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INTRODUCTION 
 
The origin of Siddha system is shrouded in mythology, tradition and religion 
of ancient manuscripts. The main aim of Siddhars denoting that the carrier of the soul 
for the attainment of happiness and to attain heavenly bliss. They found diseases as 
one of the obstacles to reach God. So they bestowed to the world the siddha medicine 
to cure diseases.  
 Word Siddha comes from the word Siddhi, which means an attainment of 
perfection or heavenly bliss. Siddhi generally refers to Attama siddhi i.e., the 
eightgreat supernatural powers. Those who attained or achieved the above said 
powers are known as Siddhars. Siddhars laid foundation for this system of medicine. 
The diagnosis of disease in siddha system of medicine relies on the eight ways 
of examination methods (Envagai thervu) as Naadi, Sparisam, Naa, Niram, Mozhi, 
Vizhi, Malam and Moothiram which are evaluated in terms of the three humours. 
According to Siddha system of medicine five elements (Earth,Water, Fire, Air, and 
Space) of nature combination with each other and form the basis of three humours of 
the body namely Vaatham, Pitham and Kabam. Whenever there is derangement in 
these three humours the resultant would be the Disease. 
“Pun” is defined as discontinuity of skin tissue in any part of the body. 
According to Siddhar aruvai maruthuvamPun is classified into 2 types (Dhutta 
viranam, Adhutta viranam). Naalavibatha pun is comes under dhutta viranam. Siddha 
system explains the naalavibatha pun formed due to abnormalities happened in the 
naalangal (veins) due to life style changes, climate and food habits.  
Naalavibatha pun may be correlated with varicose ulcer in modern science. 
The varicose ulcer (VU) is one of the most severe manifestations of chronic venous 
insufficiency (CVI) of the lower limbs, a disease of great importance to public health 
due to its high incidence, prevalence and the high socioeconomic impact that it brings, 
since it is difficult to treat and requires prolonged work absenteeism. This morbidity 
frequently presents associated with varices and trophic lesions of the lower limbs. 
Chronic venous insufficiency may be classified as a syndrome that includes from 
telangiectasia to active ulcers, originating in chronic venous hypertension caused by 
venous obstruction or reflux, with or without muscle pump insufficiency. 
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The extrapolated prevalence rate of varicose vein in India providing warning is 
about 47,928,177 in statistics. According to another estimate 15 to 20% of population 
in India is suffering vein disease.  
Despite being more common in elderly persons, with a peak of prevalence in 
individuals aged between 60 and 80 years, 22% of those affected are approximately 
40 years of age, while 13% develop VU before they reach 30 years of age, evidencing 
the losses that this disease causes in work production. Of all lower limb ulcers, 
approximately 70 to 80% are caused by CVI.  
There are multiple forms proposed for the treatment of VU, from simple 
elevation of the affected limb to surgery, including grafts and various types of 
dressings. Elevation of the limb is simple and accelerates healing of the ulcer, but 
cannot be performed isolated nor continually in patients who are not bedridden. Skin 
grafts have strict indications and can only be performed in specialized centres, in 
which surgery of the superficial system is less costly and easier to carry out, with a 
good cure rate and decreased recurrence rate, but it is only indicated in patients with a 
predominance of superficial venous system insufficiency.  
In Siddha system of medicine, drugs are prepared with ingredients of herbs, 
minerals, metals and animal origins. Siddhars used single or combination of drugs for 
their medicinal preparation. In addition to herbs little amount of Muppu Universal 
solvent or Quit essence salt) is added to increase its potency, efficacy, therapeutic 
index because of the long shelf life. Exclusivities of Siddha system are Kayakarpam, 
Attangayogam, Muppu, Varmam, Envagai thervu, manikkadai nool, Sarakkuvaippu. 
Siddhars classify the siddha medicines into 32 types of internal medicine and 32 types 
of external medicine.  
Kukkil chooranam and Thuvara ennai are one among them. Ingredients of 
Kukkil chooranam (Shorea robusta, Smilax china, Piper nigrum, Piper longum, 
Hyocyamus niger, Myristica fragrans, Terminalia bellirica, Phyllanthus emblica) and 
Thuvara ennai (Gingely oil, Terminalia chebula andAreca catechu) are having wound 
healing activity.Hence I have selected these drugs for my dissertation. 
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AIM: 
 The purpose of this trial is to evaluate the therapeutic efficacy of siddha herbo-
mineral drugs “Kukkil chooranam”(Internal) and “Thuvara ennai” (External) in the 
treatment of Pun (Naalavibatha pun- Varicose ulcer) 
OBJECTIVE:  
PRIMARY OBJECTIVE:   
 To evaluate the therapeutic efficacy of siddha drugs “Kukkil 
chooranam”(Internal) and “Thuvara Ennai” (External) in reducing pain, 
itching, oozing and healing of Varicose ulcers (Naalavibatha pun)  
SECONDARY OBJECTIVE:   
 To study the Siddha basic principles towards the efficacy of medicine.  
 To evaluate the safety of the trial drugs by doing toxicological studies 
short term and long term studies in animal models. 
 Biochemical analysis of drug. 
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LITERATURE REVIEW SIDDHA ASPECT 
Synonym:Naala suruttu pun, Narambu suruttu pun. 
Definition (Iyal): 
“Naalam” or vein is a vessel which carries the blood from a system of minute tubes 
termed capillaries to the heart. 
“Naala thaabam” is difined as inflammation of vein. 
“Pun” is defined as discontinuity or break in a bodily membrane that impedes the 
organ of which that membrane is a part from continuing its normal function. 
Aetiology: 
 
 
 
–  
According to text Siddhar Aruvai maruthuvam causes of ulcer are, 
 Derangement of three humours 
 Abscess 
 Any Trauma 
 Burns 
 Insect bite 
According to text Agasthiyar Rana vaithiyam causes of ulcer are, 
 Derangement of three humours 
 Trauma 
According to T.V.Sambavasivam pillai Dictionary causes of ulcer are, 
 Idiopathic 
 Traumatic 
Classification: 
According to text Siddhar Aruvai maruthuvam, 
 Dhushta viranam-15  
 Adhushta viranam-45  
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Other classification, 
 Derangement of three humours - Vali pun 
        - Azhar pun 
        - Iyya pun 
        - Vali pitha pun 
        - Vali iyya pun 
        - Pitha iyya pun 
        - Mukkutra pun 
        - Kuruthi pun 
        - Kuruthi thee pun 
        - kuruthi vali pun 
        - kuruthi iyya pun 
        - kuruthi vali iyya pun 
        - Kuruthi vali pitha pun 
        - Kuruthi pitha iyya pun 
        - Kuruthi mukkutra pun 
        - Velutha kuruthi pun 
 Wound caused by trauma 
According to text Agasthiyar Rana vaithiyam, 
 Dhushta viranam-4 
 Adhushta viranam 
According to text Anubava vaidhya deva ragasiyam 
 Nisa viranam(Dhushta viranam)-15 
 Aaganthuga viranam(Adhushta viranam)-49 
Others 
 Sutha ratha viranam 
 Sathiyo viranam – 8  
According to text viranakarappan roga sigitchai, 
 Nija viranam 
 Aaganthuga viranam 
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Other, 
 Sutha viranam (Simple ulcer) 
 Dhushta viranam (Chronic ulcer) 
According to T.V.Sambavasivam pillai Dictionary various type of ulcer given 
below, 
 Neruppu pun(Burns) 
 Mega pun(Venereal ulcer) 
 Vellai pun(Gonorrheal ulcer) 
 Aaraa pun(Chronic ulcer) 
 Kiranthi pun(Syphilitic secondary rashes) 
 Ottu pun(Contagious sore) 
 Kuzhi pun(Deep sore or perforating ulcer) 
 Raasa pun(Diabetic carbuncle) 
 Karappan pun(Eczema) 
 Parangi pun(Syphilitic primary sore) 
 Vettu pun(Incised wound) 
 Kaaya pun(Traumatic sore) 
 Azhi pun(Sloughing sore) 
 Korukku pun(Chancre) 
 Veditha pun(Fissurel ulcer) 
 Azhar pun(Inflammed ulcer) 
 Rasavekkadu pun(Ulcer caused by mercurial poisoning) 
 Putru pun(Fungus ulcer) 
 Vayitru pun(Gastric ulcer) 
 Thulai pun, Purai pun(Sinus) 
 Ari pun(Rodent ulcer eating away the tissues) 
According to text siddha system of disease ulcer classified into 
 Saruma pun (Dermatitis) 
 Adhirvu pun (Dermatitis traumatica) 
 Thee pun (Dermatitis calorica) 
 Kulirchi pun (Chill blains or Frost bite) 
 Azhugu pun (Dermatitis gangrenosa) 
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 Nanju pun ( Dermatitis medicamentosa) 
 Veppu noi pun (Exanthema) 
 Thinavu pun (Pruritis and Urtecaria) 
 Kirandhi (Venereal ulcer) 
 Korukku pun (Chancroid)   
Symptoms of ulcer: 
According to text Siddhar Aruvai maruthuvam, 
Due to derangement of three humours classifications of ulcers are 
 Vali pun ilakkanam:  
Ulcer is black, red or white in colour; discharge is purulent, pricking pain over 
the ulcer. 
 Azhal pun ilakkanam:  
Onset is acute, Ulcer may be yellow, red, dark red or pale red in colour. 
discharge is clear. Pain, burning sensation and redness present. 
 Iyya pun ilakkanam: 
Itching and pricking pain present, ulcer pale in colour. Discharge sticky in 
nature. 
 Vali pitha pun ilakkanam: 
Pricking pain, redness, dryness, clear and scanty discharge with foul smelling 
 Vali Iyya pun ilakkanam:  
Rough, heavy and hard, itching, pricking pain, the discharge is scanty and 
sticky in nature 
 Pitha Iyya pun ilakkanam: 
Hot, itching, burning sensation, pain, pale in colour, discharge sticky in nature. 
 Mukkutra pun ilakkanam: 
Mixture of vatha, pitha and kaba ulcer features. 
 Kuruthi pun ilakkanam: 
Red in colour, coral like, very painful, bloody discharge. Symptoms of these 
ulcers similar to dhushta viranam. 
 Kuruthi vali pun ilakkanam: 
Rough, severe pricking pain is found. Discharge is blood stained. Ulcer is red 
in colour. 
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 Kuruthi pitha pun ilakkanam: 
Ulcer is red and yellow in colour. Discharge is clear and blood stained. 
 Kuruthi iyya pun ilakkanam: 
Ulcer is red in colour, swelling, itching present. Bloody discharge present. 
 Kuruthi vali pitha pun ilakkanam: 
Mixture of of features of both kuruthi vali pun and kuruthi pitha pun 
  Kuruthi vali iyya pun ilakkanam: 
Mixture of features of both kuruthi vali pun and kuruthi iyya pun 
 Kuruthi pitha iyya pun ilakkanam: 
Mixture of features of both kuruthi pitha pun and kuruthi iyya pun 
 Kuruthi mukkutra pun ilakkanam: 
Mixture of features of both kuruthi vali pun,kuruthi pitha pun and kuruthi iyya 
pun 
 Velutha kuruthi pun ilakkanam: 
Ulcer is pale red in colour, centrally elevated, shining without any discharge. 
According to Agasthiyar Rana Vaidhyam, 
Dhushta viranam is classified into 4 subtypes, 
 Dhushta vaatha viranam: Ulcer black and white in colour, ulcer may 
be deep seated and penetrating the bone, purulent discharge present in 
ulcer, pricking pain present around the ulcer. 
 Dhushta pitha viranam:Ulcer is reddish white or yellow in colour, 
sudden onset, clear discharge present in ulcer, burning sensation and 
pain present around the ulcer,  
 Dhushta silethuma viranam:Ulcer raised, itching present, discharge 
sticky in nature, pricking pain present. 
 Rathavaatha dhushta viranam:Ulcer bright red or coral like colour, 
blood stained discharge present in ulcer. 
1. Adhushta viranam: 
Ulcer present with pus, blood discharge and purulent discharge. But this is easily 
curable. 
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2. Sutha ratha viranam: 
 Centraly elevated papular lesion that is reddish black in colour. 
Symptoms of ulcer based on three humours: 
Ulcer along with pricking pain, burning sensation, swelling and vomiting are 
caused by derangement of vaatham, pitham, kabam and ratham respectively. 
According to text Anubava Vaidhya Deva Ragasiyam, 
Sathiyo viranam: 
i. Krishta viranam: Trauma due to thorn, log, horn. It is a non-healing ulcer  
present with bleeding. 
ii. Avakartha viranam: It is a perforating and deep seated ulcer. 
iii. Vichinna viranam: Ulcer like cut wound 
iv. Piravilambi viranam: Ulcer look like cut wound, ulcer may be deep seated 
and penetrating the bone.        
v. Nibaathika viranam: In this type bone exposed in centre of the ulcer which is  
surrounded by necrotised tissue. 
vi. Vitha viranam: Traumatic ulcer caused by stones. 
vii. Pinna viranam: Ulcer caused by sword, knife like sharp instruments. 
viii. Vithalitha viranam: This is due to apply pressure over a bleeding ulcer and  
trauma. This may leads to arthralgia and development of ulcer. 
According to text Viranakarappan Roga Sigitchai: 
Nija viranam: 
 This ulcer spontaneously occurs due to derangement of humours. 
Aaganthuga viranam: 
This ulcer due to violent truma. 
Dhustha viranam: 
 Ulcer may be open or closed 
 Extensive softness or hardness present  
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 Base of the ulcer is raised or deep seated 
 Surrounding skin may be very cold or hot and pigmented 
 Purulent discharge present 
 Intolerable pain, swelling and itching were present. 
Sutha viranam: 
 Ulcer may be in pale colour and soft 
 There is no evidence of hyperpigmentation, pain, pus discharge and  
warmth. 
Common sites for the formation of ulcer according to text Agasthiyar Rana 
Vaidhyam,  
 Thol(Skin) 
 Iraichi(Muscle) 
 Perunarambu(Arteries and veins) 
 Sirunarambu(Capillaries) 
 Keel(Joint) 
 Elumbu(Bone) 
 Vayiru(Abdomen) 
 Marmasthanam(Genital organs) 
 
Common sites for the formation of ulcer according to Viranakarappan Sigitchai, 
 Thol (Skin) 
 Virai (Blood vessels) 
 Maamisam (Muscle) 
 Thasai naar (Tendon) 
 Sandhigal ( Joints) 
 Elumbu (Bone) 
 Kudalgal (GIT) 
 Marmasthaanangal (Sirasu- Head, Irudhayam- Heart, Siruneer pai-  
Urinary bladder) 
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Curable and incurable conditions: 
According to text Agasthiyar2000 (III part) 
 
 
 
 
- 
 Ulcer with pale coloured margin, oozing, pricking pain and formation 
of granulation tissue is easily curable. 
 Ulcer with pus discharge and no formation of granulation tissue are 
non-healing ulcers. 
According to text Agasthiyar Rana Vaithiyam 
Saathiya ranam: 
 Healthy adults easily recovered from this condition 
Kashta saathiya ranam: 
 Ulcer in thighs, genitalia, anus, lips, buccal cavity, jaw, eyes, teeth, tongue, blood 
vessels, ear, abdomen, axilla and breast are difficult to treat. 
According to text Siddhar Aruvai Maruthuvam 
Curable and incurable conditions: 
 Age of affected person 
 If the shape of  the ulcer is oval, triangle and rectangle are easily curable 
 Ulcer in eye, nostrils, gums, chest, nipple and joint are difficult to treat. 
 Ulcer in diabetes, TB, leprosy and syphilitic ulcer are called non healing ulcer 
 Improper medication may delay the healing process 
 Ulcer with pus discharge, raised floor, fissures and deep wound are not curable 
 Ulcer in Vertex, fingertip, vital points (varmam), deep seated wound which 
penetrate the bone and bone marrow are not curable. 
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According to text Viranakarappan Sigitchai, 
Easily curable wound are, 
 Ulcer in healthy adults 
 When shape of the ulcer is circular or oval 
 When edges of the ulcer is clean  
 Ulcer in male genitalia, lips, buccal cavity and cheeks 
According to text Viranakarappan Sigitchaicauses of delayed wound healing, 
 Inflammation of tendon with pus discharge 
 Surgical removal of blood vessels 
 Deep seated ulcers 
 Secondary infection in ulcer 
 Fracture of bones 
 Improper removal of foreign particles 
 Toxic bite induced ulcer 
 Improper medication 
 Irritation of wound by any other object 
 Stress 
 Alcoholism 
 Abnormal sleeping pattern 
SIDDHA PATHOLOGY 
According to Siddha system of medicine five elements (Earth,Water, Fire, Air, 
and Space) of nature combined with each other and form the basis of three humours 
of the body, namely Vali (Vatham), Azhal (Pitham) and Iyam (Kapham). Whenever 
there is derangement in these three humours the resultant would be the Disease. 
Vaatham is responsible for all physiological and biological activities of the body. 
Derangement of vaatham leads to stagnation of blood in the affected part of the body. 
The blood vessels which contain stagnated blood get dilated, coiled and become more 
prominent. After that inflammatory process occurs at the site due to derangement of 
pitham. The deranged vaatham and pitham simultaneously leads to derangement of 
kabham which is responsible for the formation of ulcer in the affected part of the 
body.   
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PINIYARI MURAIMAI(DIAGNOSTIC METHODS): 
 Piniyarimuraimai is the method of diagnosing disease. It is based on the 
following principles: 
 Poriyal aridhal 
 Pulanal aridhal 
 Vinaathal 
 Poriyal aridhal and Pulanal aridhal means examining the patient‟s „Pori’ and 
„Pulan’ with that of physician‟s „Pori’ and „Pulan’. 
Imporigal 
 Mei (Skin)  
 Vai (Tonge) 
 Kan (Eyes) 
 Mooku (Nose) 
 Sevi (Ear) 
Impulan: 
 Osai (Sound) 
 Ooru (Sensation) 
 Oli (Vision) 
 Suvai (Taste) 
 Naatram (Smell) 
Vinathal: 
„Vinaathal’ is a method of enquiring about the details of the patient‟s problem from 
his own words or from his parents or attenders who are taking care of the patient, 
when the patient is not able to speak (or) if the patient is a child. 
 
ENVAGAI THERVUGAL (Eight tools of examination) is: 
 
 
 
 
 
 
 
–  
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Naadi (Pulse) 
  In pun, the following types of Naadi could be felt. They were, 
a) Iyya naadi 
b) Vatha kaba naadi 
 
 
 
 
–  
 
 
 
 
–  
 
Sparism - Test sensation, temperature and nature of the skin  
Naa   - Test theColour of saliva, colour of sputum and nature of speech. 
Niram  - Test theVariation in pigmentation of skin. 
Mozhi-  - Vaatham (Normal pitch) 
   -  Pitham (High pitch) 
   -  Kabam (Low pitched)  
   -  Thontham (Mixed all the above) 
Vizhi  -  Vaatham (Black in colour, increased lacrimation)) 
   -  Pitham (Yellow or red in colour) 
   -  Kabam (White in colour)  
Malam -  Vaatham (Stools are black in colour and constipated) 
   -  Pitham (Yellowish white in colour) 
   -  Kabam (White in colour)  
   -  Thontham (Mixed colour) 
Moothiram 
  Collection of urine for the determination of Neerkkuri and Neikkuri, is an 
important diagnostic method  
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 Neerkkuri 
 
 
–  
 
Prior to the day of urine examination the patient is instructed to take a balanced 
diet. The patient should have good sleep. After waking up in the morning, the first 
urine voided is collected in a clear wide mouthed glass container and is subjected to 
analysis of “Neerkkuri” within one and a half an hour. 
 Neikkuri 
 The collected specimen (Urine) is kept open in a glass dish or china clay 
container. It is to be examined under direct sunlight, without any shaking of the vessel. 
            Then add one drop of gingelly oil without disturbing the urinary specimen and 
the neikkuri was noted in direct sunlight and conclude the diagnosis as follows,  
Character of Vaathaneer 
  
 When the oil drop lengthens like a snake, it is called “Vaathaneer” 
Character of Pithaneer 
  
 When the oil drop spreads like a ring, it is called “Pithaneer 
Character of Kabhaneer 
 
 When the oil drop appears like a pearl, it is called “Kabhaneer” 
Character of Thonthaneer 
 “  
  
  
 
 Snake in the ring, ring in the snake, snake in the pearl and ring in the pearl are the 
characters of Thontha neer.  
LINE OF TREATMENT 
 
- 
 
 Thiruvalluvar says in “Thirukkural” about physician‟s duty to study the disease, 
Study the cause, seek subsiding ways and do what is proper and effective. 
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–  
 
            In Siddha system of medicine, the main aim of the treatment is to cure 
Udalpini and Manapini. Treatment is not only for perfect healing but also for 
prevention and rejuvenation. In siddha system of medicine line of treatment are as 
follows, 
 Neekam (Treatment) 
 Niraivu (Rejuvenation) 
 Kappu (Prevention) 
Neekam (Treatment) 
  
  
  
  
 
Virechanam: 
Siddha system of medicine is based on three humours and hence the treatment is 
mainly aimed to bring the three humours to equilibrium state and thereby restoring the 
physiological condition of the seven thathus. 
 
 
 
Internal medicine: 
The medicines which are taken internally are called as internal medicines. These are 
classified into 32 types, e.g. surasam, saaru, pittu, vadagam and chooranam 
External medicine: 
The medicines which are applied externally are called as external medicines. These 
also classified into 32 types, e.g.kattu, patru, otradam, vedhu and thokkanam. 
 
According to text sinthamani- gantharuvathathai ilambagam- 324 management 
of wound described as follows: 
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-  
 When there is a traumatic injury in the body the following treatments and therapies 
can be followed, 
1) Nei kizhi: A cloth bundled with herbs, which is soaked with heated medicated oil 
and given foementation. 
2) Ennai patharil kidathal: The affected person is made to lie down into a tub filled 
with medicated oil. 
3) Removal of foreign particles: When there is a foreign particle at the site of wound 
like iron or any other metallic object, it is cut and cleaned as per procedure. 
4) Application of medicines. 
5) Covering the wound: The wound is covered with a small corpet made out of rat 
hair.   
Anubanam: 
-- 
–  
 
–  
 
Pathiyam (Dietary Regimen): 
           In mild conditions of the disease, salt and tamarind can be taken in little 
quantities. When the condition is severe, tamarind should be avoided and salt must be 
consumed after frying. 
 
 
 
–  
 
Niraivu (Rejuvenation) 
Substances used for neutralising the three humours are: 
 
 
 
 
      –  
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The patients are well motivated. The nature and course of the disease is explained 
to them, Life-style modification advised. 
Kappu (Prevention) 
  Ideal measures mentioned in the Siddha classical text Pathartha guna 
chinthamani for healthy living as below, 
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MORDEN ASPECT
   
STRUCTURE OF SKIN: 
  Skin is not an inert wrapping but a dynamic membrane consisting of large 
number of structures and capable of performing numerous functions. It is the 
largest body organ contributing more than 15 percent of the body weight. It consist 
of three layers, 
 Epidermis 
 Dermis 
 Subcutaneous tissue 
Epidermis: 
 Epidermis is 0.5 mm to approximately 2 mm in thickness and is composed of 
various layers which are as follows from outward to inward 
 Stratum corneum 
 Stratum lucidum( only palm and sole) 
 Stratum granulosum 
 Stratum spinosum 
 Stratum germinativum 
1. Stratum germinativum: 
It (Basal cell layer) is the innermost layer of the epidermis. The major cells of this 
layer are keratinocytes which are columnar in shape and wedge in between these cells 
are melanocytes and Langerhans cells. The keratinocytes keep on dividing and move 
outwards undergoing change in shape, size and constituents. This process is known as 
“keratinization”. The skin is being shed off every day unseen to the naked eyes and the 
whole epidermis is replaced in about a month time. Melanocytes synthesize and 
distribute melanin to keratinocytes and are responsible for the complexion of an 
individual. Langerhans cells are the immunogenic cells. 
2. Stratum spinosum: 
It (Prickle cell layer) is so named due to the spine like appearance of the cell 
margins in histologic sections. The spines like structures promote adhesion of 
epidermal cells and resist mechanical stresses. The cells in this layer contain bundles 
of keratin filaments. 
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3. Stratum granulosum: 
It (Granular cell layer) has 3-4 layers of elliptical cells which contain prominent 
basophilic kerato-hyalin granules. 
4. Stratum lucidum: 
It is present only on palms and soles and is situated between stratum granulosum 
and stratum corneum. 
5. Stratum corneum: 
It is compossed of multiple layers of flattened, dead horny cells which are the 
largest epidermal cells. These cells provide protection and act as barrier to the 
environment. 
Epidermmal appendages: 
 Sebaceous glands 
 Sweat glands 
 Hair  
 Nails 
Dermo-epidermal junction (Basement membrane) 
The dermo-epidermal junction forms an extensive interface between the epidermis 
and the dermis which play a key role in epidermal dermal interactions. It consist of 
several planes, i.e. lamina lucida (basal portion of keratinocytes), lamina densa and the 
fibro reticularis. It provides support for epidermis and serves as a semipermeable 
barrier. 
Dermis: 
It varies in thickness from 1mm on the eyelid and 5mm on the back. It is a complex 
system consisting of a supporting matrix, several fibrous and filamentous tissue, 
epidermally derived appendages, cellular components like fibroblasts, mast cells,  
macrophages, blood borne cells (lymphocytes, plasma cells, other leukocytes) and 
nerve and vascular networks. The dermis consist of, 
 Papillary dermis 
 Reticular dermis 
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i. Ground substance or the supporting matrix: 
It consist of acid mucopolysaccharides and proteins. The main fibrous 
connective tissues of the dermis are collagen and elastic fibers. Collagen fibers are soft 
and flexible but strong and inelastic. The elastic fibers form a continuous network 
throughout the dermis and extend from dermo-epidermal junction to the subcutis and 
provide elasticity to the skin. Collagen fibers account for 75% and elastic fibers 3% of 
the dry weight of the skin. 
ii. The cellular components of the dermis: 
These are fibroblasts, mast cell, macrophages, monocytes and dendrocytes. 
Fibroblasts are the most common cells found in the dermis. They synthesize and 
degrade fibrous and nonfibrous proteins of the connective tissue and the matrix. Mast 
cells are present in large numbers in the papillary dermis around the appendages and 
blood vessels. They liberate histamine and other mediators in IgE mediated 
hypersensitivity reactions. The monocytes, macrophages and dendrocytes are 
immunogenic cells and participate in various immune mediated reactions. 
iii. Vascular network: 
The skin has rich supply of vascular network. Blood vessels from two 
plexuses, i.e. the superficial plexus in the papillary dermis and deep plexus in the 
lower part of the reticular dermis adjoining the subcutaneous tissue around the adnexa. 
Lymphatics roughly parallel the major vascular plexuses and clear the tissues of 
unwanted material. 
iv. Nerve network: 
The network of nerve in the skin consists of somatic sensory fibres and 
sympatheticautonomic fibres. Sensory fibres perceives the sensation of touch, pain, 
temperature, itching and mechanical stimuli while autonomic motor fibers control 
cutaneous vascular tone, pilomotor responses and sudoromotor activity. The smooth 
and involuntary muscles of the skin occur as arrector pili, tunica dartos of the external 
genitalia and in the areola of the nipples. 
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Subcutaneous tissue (Hypodermis) 
The subcutaneous tissue consist of lobules composed of adipocytes (fat cells) 
separated by thin fibrous septa through which small vessels pass. Adipocytes has a 
cytoplasm with membrane bound lipids that displace the nucleus to the periphery. 
Subcutaneous fat act as shock absorber, insulator for heat, stores triglycerides which 
serve as a source of energy upon break down. 
Functions of the skin: 
 Protection (From physical, chemical and biological injuries) 
 Perception (Sensation like touch, pain, temperature and vibration) 
 Temperature regulation (Through eccrine sweat glands and rich blood 
supply) 
 Barrier function (Act as permeability barrier) 
 Secretory function (Synthesis of vitamin D3) 
 Storage function (Subcutaneous fat stores energy and other compounds) 
 Excretory function (Some harmful substances are excreted through skin) 
 Immunological function (Antigen specific cell responses are carried out in 
the skin) 
 Cosmetic function (Colour and texture of the skin along with hair and nail 
play an important role in aesthetic appeal of an individual) 
 VENOUS DRAINAGE OF LOWER LIMB:  
Consideration of the venous drainage is of great importance because in the 
lower limb venous blood has to ascend against gravity. This is aided by a number 
of local factors, the failure of which gives rise to varicose vein. The veins are 
classified into 3 groups: 
 Superficial veins 
 Deep veins 
 Perforating veins 
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a. Superficial veins: 
  They include the great and small saphenous veins and their tributaries. They lie 
in the superficial fascia, on the surface of the deep fascia. They are thick-walled 
because of the presence of smooth muscle and some fibrous and elastic tissues in 
their walls. Valves are more numerous in the distal parts of these veins than in their 
proximal parts. A large proportion of their blood is drained into the deep veins 
through the perforating veins  
i) Long saphenous vein: 
 This is the largest and longest superficial vein of the lower limb 
(Saphes=easily seen). This vein begins on the dorsum of the foot by union of the 
medial end of the dorsal venous arch with the medial marginal vein. It ascends in 
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front of the medial malleolus. In the lower one-third of the leg, it passes obliquely 
across the medial surface of the tibia. In the upper two-thirds of the leg, the vein 
ascends along the medial border of the tibia, to the posteromedial side of the knee. 
In the thigh, it inclines forwards to reach the saphenous opening where it pierces 
the cribriform fascia and opens into the femoral vein. Before piercing the 
cribriform fascia, it receives three named tributaries corresponding to the three 
cutaneous arteries, and also many unnamed tributaries. 
 
Surface marking: 
Its centre lies 4cm below and 4cm lateral to the pubic tubercle. It is about 2.5 cm 
long and2cm broad, with its long axis directed downwards and laterally. It can be 
marked by joining the following points 
 First point on the dorsum of foot at the medial end of the dorsal venous  
arch. 
 Second point on the anterior surface of the medial malleolus 
 Third point on the medial border of the tibia at the junction of the upper     
Two thirds and lower one-third of the leg. 
 Fourth point at the adductor tubercle. 
 Fifth point just below the centre of the saphenous opening. 
It contains about 10-20 valves. There is one valve that lies just before the vein 
pierces the cribriform fascia and another at its termination into the femoral vein. 
Tributaries: 
 At the commencement- Medial marginal vein from the sole. 
 In the leg- It communicates freely with the small saphenous vein and with deep 
veins. 
 Just below the knee- 1) The anterior vein of the leg, 2) The posterior arch vein, 
3) A vein from the calf. 
 In the thigh- 1) The accessory saphenous vein, 2) The anterior cutaneous vein 
of the thigh 
 Just before piercing the cribriform fascia- 1) Superficial epigastric vein, 2) 
Superficial circumflex iliac vein, 3) Superficial external pudendal vein. 
 Just before termination- Deep external pudendal vein. 
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 The thoracoepigastric vein runs along the anterolateral wall of the trunk. It 
connects the superficial epigastric vein with the lateral thoracic vein. Thus very 
important connection between the veins of the upper and lower limbs. 
ii) Small or Short saphenous vein: 
The vein is formed on the dorsum of the foot by the union of the lateral end of the 
dorsal venous arch with the lateral marginal vein. It enters the back of the leg by 
passing behind the lateral malleolus. In the leg, it ascends lateral to the 
tendocalcaneus, and then along the middle line of the calf, to the lower part of the 
popliteal fossa. Here it pierces the deep fascia and opens into the popliteal vein. It 
drains the lateral border of the foot, the heel and the back of the leg. It is connected 
with the great saphenous and with the deep veins and is accompanied by the sural 
nerve. 
Surface marking: 
It can be marked by joining the following points, 
 A point on the dorsum of the foot at the lateral end of the dorsal venous  
arch. 
 Second point behind the lateral malleolus. 
 Third point just lateral to the tendocalcaneus above the lateral  
malleolus. 
 Fourth point at the centre of the popliteal fossa. 
Just before piercing the popliteal fascia, it may give a communicating branch to 
the accessory saphenous vein.Sometimes the whole of the small saphenous vein 
opens into the great saphenous vein through the accessory saphenous vein. 
Occasionally the small saphenous vein ends below the knee either in the great 
saphenous vein or in the deep muscular veins of the leg. 
b. Deep vein: 
These are the anterior and posterior tibial, peroneal, popliteal and femoral 
veins and their tributaries. They accompany the arteries and are supported by 
powerful surrounding muscles. The valves are more numerous in deep veins than in 
superficial veins. They are more efficient channels than the superficial veins 
because of the driving force of muscular contraction.  
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c. Perforating veins: 
These are connects the superficial veins with the deep veins. These are 
classified into 2 groups: 
 Indirect perforating vein 
 Direct perforating vein 
Indirect perforating veins: 
These are connecting the superficial veins with the deep veins through the muscular 
veins. 
Direct perforating veins: 
These are connecting the superficial veins directly with the deep veins. The great 
and Small saphenous veins are the largest direct perforators. The small perforating 
veins are summarised below, 
 In the thigh- The adductor canal perforator  
 Below the knee- One perforator connects the great saphenous vein or the  
posterior arch vein with the posterior tibial vein. 
 In the leg- 1) A lateral perforator, 2) The upper medial perforator, 3) The  
middle medial perforator and 4) The lower medial perforator. 
Factors helping venous return: 
General factors: 
 Negative intrathoracic pressure which is made more negative during 
inspiration 
 Arterial pressure and overflow from the capillary bed 
 Compression of veins accompanying arteries by arterial pulsation 
 Valves which support the long column of blood and maintain a unidirectional 
flow. 
Local factors: 
 Venous: Veins of lower limb are more muscular than the veins of other part of 
the body. They have number of valves. Superficial veins are connected to deep 
veins by perforators. 
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 Muscular: When the limb is active, muscular contraction compresses the deep 
veins and drives the blood in them upwards. 
 Fascial: The tight sleeve of deep fascia makes muscular compression of the 
veins much more effective by limiting outward bulging of the muscles. 
LEG ULCERS: 
Leg ulcers are common medical condition, affecting 3% to 5% of the 
population over the age of 65. The cause of the leg ulceration is venous insufficiency 
alone in 45% to 60% of cases, arterial insufficiency in 10% to 20%, diabetes mellitus 
in 15% to 25% or combination in 10% to 15%. Smoking and obesity increase the risk 
for ulcer development and persistence, independent of the underlying cause.  Defining 
the cause of the leg ulceration is important in healing the ulceration.  However except 
in the cause of significant arterial insufficiency, most leg ulcers can be healed without 
treating the anatomic underlying cause.   
The wound healing response is complex, involving intricate interactions between 
different cell types, structural proteins, growth factors and proteinases. Normal wound 
repair consist of three phases- inflammation, proliferation and remodelling. Those 
occur in a predictable sequence and comprise a series of cellular and bio chemical 
events.  Abnormalities in any one of these components can produces delayed or 
ineffectual wound healing.  
CLASIFICATION OF ULCER: 
Mainly ulcers are classified in to two types 
 Clinically  
 Pathologically 
I. Clinically 
 Healing ulcer 
 Spreading ulcer 
 Callous or chronic ulcer 
II. Pathologically 
 Non-specific ulcers – traumatic  
- Arterial 
- Venous 
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- Neurogenic (trophic) 
- Associated with malnutrition 
- Ulcer due to other diseases 
 Specific ulcers  (eg. Tuberculous, syphilitic) 
 Malignant ulcers (eg. Epithelioma, marjolins ulcer) 
VARICOSE ULCER 
Synonyms – post thrombotic ulcer, gravitational ulcer 
Definition: 
Venous ulcer also known as stasis ulcer is the most common aetiology of lower 
extremity ulceration. Venous ulceration result from increased pressure in the venous 
system of the lower limb.  Most common cause is insufficiency of the valves in the 
deep venous system and lower perforating veins of the lower leg. This is mostly 
occurs in the age of 40 to 60 yrs. Women are most commonly affected than men. 
Epidemiology: 
The extrapolated prevalence rate of varicose vein in India providing warning is 
about 47,928,177 in statistics. According to another estimate 15 to 20% of population 
in India is suffering vein disease. 
Despite being more common in elderly persons, with a peak of prevalence in 
individuals aged between 60 and 80 years, 22% of those affected are approximately 40 
years of age, while 13% develop VU before they reach 30 years of age, evidencing the 
losses that this disease causes in work production. Of all lower limb ulcers, 
approximately 70 to 80% are caused by CVI.  
The first venous stasis ulcer episode occurs in average, five years after the 
diagnosis of CVI and, in patients with VU, 47% have already had two or more 
ulceration episodes, whereas 21% of them have already had six or more episodes. The 
annual recurrence rate varies from 33 to 42%. In general, 60% of the ulcers remain for 
a period of 6 months or longer, and over 40% of them persist for more than one year. 
The mean duration is 6 to 9 months, varying from 4 weeks to 72 years.  
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Causes: 
Varicose vein: 
 Incompetence of valves -  Sapheno-femoral junction(SFJ) 
           -  Sapheno-popliteal junction(SPJ) 
-  Perforator  
 Reflux in superficial veins -  Long saphenous vein (LSV) 
     -   Short saphenous vein (SSV) 
 Reflux in deep veins -  Femoral vein 
      - Popliteal vein 
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Classification of causes: 
 Primary  - Congenital 
 Secondary - Pregnancy 
-  Abdominal or pelvic mass 
   -  Ascites 
   -  Obesity 
   -  Constipation 
   -  Thrombosis of leg veins 
     -  Spend long period of time standing 
Predisposing factors: 
 Old age 
 Obesity 
 Female 
 Pregnancy 
 Hypertension 
 Lower socio-economic status 
 Previous injury 
 H/O Deep vein thrombosis 
 Congestive heart failure 
 Anaemia 
 Zinc deficiency 
 Defective fibrinolytic system 
Classification: 
a) Clinical  - C0: No visible or palpable sings of venous disease 
   -  C1: Telangiectasies or reticular vein 
-  C2: Varicose veins 
-  C3: Oedema 
-  C4: Pigmentation or oedema, Lipodermatosclerosis 
-  C5: Healed venous ulcer 
-  C6: Active venous ulcer 
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b) Etiological  – Congenital 
    - Primary 
     - Secondary 
 
c) Anatomic – Superficial veins 
- Perforator veins 
- Deepvein 
 
d) Pathophysiology: 
 
Venous blood from lower limb are pumped into heart through various factors, 
one of the main factor is calf muscle pumping. With each contraction of the calf, blood 
should be pumped to the heart (muscle pump).  Intact valves in the lower leg are 
required to prevent this pumped blood from reflexing out through the perforators in to 
the superficial system.  The hypertrophy of these superficial veins is marked by the 
development of varicose veins.  Increased pressure on the iliac veins from pregnancy 
or obesity or simple inactivity may also result in the appearance of venous 
insufficiency as well.  The valvular insufficiency results in disorder in the venous and 
capillary circulation in the leg.  Valve insufficiency may occur from prior 
thrombophlebitis or congenital weakness.  
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Clinical features: 
 Ulcer present in lower part of the leg on medial side.  These are never seen 
above the junction of the middle and upper third of the leg. 
 Varicose ulcer can be of any shape and size. 
 The ulcer is painful in the beginning but in chronic it becomes painless. 
 The discharge is seropurulent with occasional trace of blood. 
 The surrounding  skin is shows signs of chronic venous hypertension 
(pigmentation, induration and tenderness) 
 Regional lymph nodes (inguinal nodes) are only enlarged if the ulcer becomes 
infected. 
 Squamous carcinoma can be arising from the margin of the long standing 
venous ulcer.  When the edge of the ulcer is raised and everted or somewhat 
different from described above should arouse suspicion of malignancy. 
 The base of the ulcer becomes hard.  The malignant ulcer is called marjolin’s 
ulcer.   
 Discomfort and tenderness of the skin. 
 Pigmentation and eczema exist for months or years before a ulcer develops. 
 Swelling that subsided with elevation 
 Ulcer may appear on the background of stasis dermatitis. 
 Granulation tissue and fibrin present 
MODERN ASPECT 
 
 Page 33 
 
 Oedema and fibrosis present over the medial aspect of the ankle and lower third 
of the shin. 
 Following a minor trauma a macular haemorrhage appears, this is the 
premonitory sign often impending ulceration.  
 Lower extremities varicosities present 
On physical examination: 
 Varicose ulcer can be of any shape and size. 
 The edges are slopping and pale purple- blue in colour. 
 The margin is thin and blue of growing epithelium. 
 The floor is formed by pale granulation tissue. 
 The ulcer is usually shallow and flat and never penetrates the deep fascia. 
 The discharge is seropurulent with occasional trace of blood. 
 The base of the ulcer is fixed to the deeper structures. Granulation tissue and 
fibrin present in base of the ulcer 
 The surrounding  skin is shows signs of chronic venous hypertension 
(pigmentation, induration and tenderness) 
 Venous dermatitis with hyperpigmentation and hemosiderosis or haemoglobin 
deposition in the skin. 
 There may be scare of previous ulcer  
 Regional lymph nodes (inguinal nodes) are only enlarged if the ulcer become 
infected. 
 Lower extremities varicosities present 
 Swelling of  lower limb 
 Lipodermatosclerosis with thickening and fibrosis of normal adepose tissue 
under skin. 
Complications: 
 Cellulitis 
 Osteomyelitis 
 Malignant changes 
 Haemorrhage  
 Periosteitis 
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DIFFERENTIAL DIAGNOSIS 
Traumatic ulcer –this ulcer can be caused by either mechanical, physical or 
Chemical injury. This ulcers heels quickly unless supervened by infection or 
ischaemia.  Which may turn this ulcer to chronicity. 
Ischaemic or arterial ulcer - this ulcer due to peripheral arterial diseases, and 
poor Peripheral circulation.This is more often seen in older people and younger men 
between 20 to 40 yrs of age.  In this ulcer patches of dry gangrene may be present 
along with ulcer.  This ulcers are occurs on the anterior and outer aspect of the leg, 
dorsum of the foot, on the toes or the heel. Pain is main complaint of this disease.   An 
arterial ulcer occurs below the medial malleolus. There is history of intermittent 
claudication and resting pain in majority of cases.  If the leg is kept elevated above the 
heart level the ulcer shows no sign of healing and patient will complaint of pain in this 
position.  On examination these ulcers are punched out with destruction of deep fascia. 
Tendons, bones, and under lying joints may be exposed on the floor of the ulcer. 
Which covered by minimal granulation tissue.  Presence of ischaemic changes can be 
detected on the foot (pallor, dry skin, loss of hair, fissuring of nails).  Pulse of dorsalis 
pedis artery this always either feeble or absent.   
Trophic ulcer (neurogenic) – these ulcer have punched out edge with slough 
in the floor thusresembling a gummatous ulcer. (eg. Bed sore and perforating ulcers ). 
These ulcer develop as the result of repeated trauma to the in sensitive part of the 
body.  These ulcers are commonly seen on the heel and the ball of the foot.  When the 
patient is ambulatory, on the buttock and on the back on the heel when the patient is 
non ambulatory.  The ulcers start with callosity under which suppuration takes place, 
the pus comes out and the central hole forms the ulcer which gradually burrows 
through the muscles and tendons to the bone.  Floor is covered with offensive slough 
and tendons and even bones can be seen here.  The surrounding skin has no sensation. 
The cause may be spinal or leprosy or peripheral nerve injury, diabetic neuropathy, 
tabes dorsalis, transvers myelitis or meningomyelocele. 
Tuberculous ulcer – this mostly result from bursting of caseous lymph nodes 
are from abseess from bone and joint tuberculosis and breaks out on the surface.  
Ulcer is slightly painful usually seen in the neck and groin.   The features of ulcer is its 
edge which is thin, reddish blue and determined, pale granulation tissue with scanty 
serosanguineous discharge in the floor and slight induration at the base.  The regional 
lymph node are enlarged, non-tender and matted.   
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Syphilitic ulcer – hard chancre appears on the external genitalia 3 or 4 weeks 
after infectionin the first stage of this disease.  It is painless and possesses a 
characteristic indurated base, which feels like a button.  Lymph nodes are enlarged.   
Extra genitalia chancres which are seen in the nipple, lip, tongue and anal canal are 
not often indurated.  
Meleney’s ulcer – these ulcers are seen the postoperative wounds either after 
the operation for perforated viscus or for drainage of emphyema throacis.  This type 
of ulcer is due to symbiotic action of micro aerophilic non haemolytic streptococci 
and haemolytic staphylococcus aureus. It is a grangenous wound fallowing any 
operation.  Rarely is it seen on the leg or on the dorsum of the hand.  It is spreading 
ulcer which is painful with signs of toxaemia.   The floor contains aboundent foul 
smelling granulation tissue with copious seropurulent discharge. It is surrounded by 
deep purple zone, which in turn is surrounded by an outer zone of erythema.This 
particular condition is painful, toxaemic and the generalcondion deteriorates without 
treatment. If it is not treated the patient’s general condition deteriorates and he will 
die ultimately.   
Examination: 
 Abdomen mass 
 Peripheral pulses 
 Pattern of varicosities – LSV/ SSV 
 Trendelenburg test 
Investigation: 
 Doppler 
 Air plethysmography – Venous refilling time 
 Venogram 
 Duplex scan 
 USG Abdomen/pelvis 
 Ulcer – Swab culture, TWDC 
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Treatment: 
a) Non –surgical  – Compression stockings 
    - Wound dressing 
    - Weight reduction 
    - Pharmacotherapy 
    - Leg elevation at rest 
b) Surgical           - High saphenous ligation 
    - Endovenous laser ablation 
    - Endovenous radio-frequency ablation 
    - Sclerotherapy 
Prevention: 
 Be active, moving the leg muscles keeps the blood flowing. 
 Keep your blood pressure under control. Work with your doctor. 
 To temporarily relieve symptoms, lie down and raise your legs at least six inches 
above the level of your heart. Do this for ten minutes a few times each day. 
 Maintain a normal body weight. 
 Wear prescription compression stockings as specified by your doctor. 
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INTERNAL MEDICINE 
KUKKIL 
Botanical Name : Shorea robusta, Gaertn.f.  
English Name : Sal tree 
Family  : Dipterocarpaceae  
Organoleptic Character 
Taste  : Kaippu 
Potency : Veppam 
 Division : Kaarpu 
 
 
- 
 
 
Actions: 
 Stimulant 
 Expectorant 
 Diuretic 
 
PARANGIPATTAI 
 
Botanical Name : Smilax china.Linn  
English Name : China root 
Family  : Liliaceae  
Organoleptic Character 
Taste  : Inippu 
Potency : Thatpam 
 Division : Inippu 
 
 
–  
 
 - 
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Chemical constituents: 
 Sarasapogenin 
 Cortisone 
Actions: 
 Alterative 
 Antisyphilitic 
 Aphrodisac 
 Depurative 
   
GANDHAGAM 
 
English Name : Sulphur 
Organoleptic Character 
Taste  : Kaippu, Thuvarppu 
Potency : Veppam and Thatpam 
 
  
 –  
  
  
Action: 
 Laxative 
 Tonic 
 Antiseptic 
 Diaphoretic 
 Cholagogue 
 
MILAGU 
Botanical Name : Piper nigrum 
English Name : Black pepper 
Family  : Piperaceae 
Organoleptic Character 
Taste  : Kaippu, kaarppu 
Potency : Veppam 
Division : Kaarppu 
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- 
 
 
 
Chemical Constituents: 
 A volatile alkaloid Piperine or Pipirine 5-9%, Piperidine or Piperidin 5%, 
Abalsamic volatile essential 1-2%, fat7%.Mesocarp contains chavicin, a balsamic 
volatile oil, starch, gum, Piperrettine, Piperanine, Pipericide Sarmentine, Eugenol. 
  Ref: Indian Herbal Pharmacopoeia, P – 321. 
Actions: 
 Carminative 
 Pungent 
 Antiperiodic 
 Analgesic 
 Anti- inflammatory 
 Antioxidant 
 Cyclooxygenase inhibitory activity 
Ref: Indian Herbal Pharmacopoeia, P – 324 Database, Vol. – 190. 
 
THIPPILI 
 
Botanical Name : Piper longum 
Synonym   : Charica roxburgii 
Family  : Piperacae 
Organoleptic Character 
Taste  : Kaarppu 
Potency : Veppam 
Division : Kaarppu 
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 - 
  
–  
 
Chemical Constituents: 
 Piperine (4 – 5%), Volatile Oil, Piperlonguminine,Piplartine, Sesamin, 
Terpenoids, Resin, Piperundecalidine. 
  Ref: Indian Herbal Pharmacopoeia revised – 2002, P – 310, 311. 
Actions: 
 Stimulant 
 Carminative 
 Alterative 
 
KUROSANI OMAM 
 
Botanical Name :  Hyocyamus niger.Linn 
English Name :  Henbane seed, Black henbane 
Family  :  Solanaceae 
Organoleptic Characters 
Taste  : Kaarpu, Kaippu. 
Potency :  Veppam 
Division :  Kaarppu 
 
 
 
 
–  
Chemical Constituents: 
 Hyoscyamine 
 Hyoscyine 
 Scopolamine 
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Action: 
 Antispasmodic 
 Anodyne 
 Hypnotic 
 Sedative 
 Mild diuretic 
 
JATHIKKAI 
 
Botanical Name :  Myristica fragrans Houtt 
English Name :  Nut meg 
Family  :  Myristicaceae 
Organoleptic Characters 
Taste  : Thuvarpu, Karppu. 
Potency :  Veppam 
Division :  Kaarppu 
 
 
–  
 
   
Chemical Constituents: 
 Myristicine 
Action: 
 Stimulant 
 Carminative 
 Narcotic 
 Aromatic 
 Aphrodisiac 
 Tonic 
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JATHIPATHIRI 
 
Botanical Name :  Myristica fragrans Houtt 
English Name :  Arillus of the nut(Maca) 
Family  :  Myristicaceae 
Organoleptic Characters 
Taste  : Karppu, Thuvarpu. 
Potency :  Veppam 
Division :  Kaarppu 
 
 
–  
 
–
Action: 
 Stimulant 
 Carminative 
 Aphrodisiac 
 Hypnotic 
 
THANDRIKAI 
 
Botanical Name : Terminalia Bellerica. Roxb. 
English Name : Beleric Myrobalan. 
Family  : Combretaceae 
Organoleptic Characters 
Taste  : Thuvarppu 
Potency : Veppam 
Division : Inippu 
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Chemical constituents: 
Main chemical constitutes are tannins mainly include ß- sitosterol, gallic acid, ellagic 
acid, ethyl gallate, galloyl glucose and chebulaginic acid. 
Action: 
Tannins: It shows scavenging activity against mitochondrial lipid peroxidation. It 
causes significant decrease in cholesterol level and it also shows antimicrobial activity against 
bacteria and virus with a significant inhibition of microsomal lipid peroxidation and reduction 
in triglyceride levels in liver and reduction in total acidity and peptic activity and increase in 
mucin content. 
Ref: Indian Herbal Pharmacopoeia. 
SEERAGAM 
 
Botanical Name : Cuminum cyminum.Linn     
English Name : Cumin seeds or fruit 
Family  : Apiaceae 
Organoleptic Characters 
Taste  : Karppu, Inippu 
Potency : Thatpam 
Division : Inippu
  - 
 
  
–  
  
–  
 
Chemical Constituents: 
 Thymene 
 Cuminol 
 Cymene 
Action: 
 Carmiative 
 Stimulant 
 Stomachic 
 Astringent 
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CHITRARATHAI 
 
Botanical Name : Alpinia officinarum 
English Name : Lesser galangal 
Family  : Zingiberaceae 
Organoleptic Characters 
Taste  : Karppu 
Potency : Veppam 
Division : Karppu 
 
  
–  
  
–  
 
Chemical Constituents: 
 Galangol 
 Galangin 
Action: 
 Expectorant 
 Febrifuge 
 Stomachic 
 
NELLIMULLI 
 
Botanical Name : Phyllanthus  Emblica 
English Name : Indian gooseberry 
Family  : Euphorbiaceae 
Organoleptic Characters 
Taste  : Pulippu, Thuvarppu, Inippu 
Potency : Thatpam 
Division : Inippu 
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–
     
Chemical Constituents: 
Ascorbic acid, high density of ellagitannins such as emblicanin A (37%), 
emblicanin B (33%), Punigluconin (12%) and pedunculagin (14%). Polyphenols: 
Flavonoids, Kaempferol, ellagic acid and gallic acid. 
Action: 
 Astrigent 
 Diuretic 
 Laxative 
 Refrigerant   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERNAL MEDICINE 
 
 Page 46 
 
Internal Medicine 
 
NellikkaiThanni kai 
 
 
 
 
 
 
 
 
 
Kurasani OmamChittaratai 
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 Parangi pattai                                                        Kukkil 
 
 
 
 
 
 
 
 
 
 
 
                             KanthagamMilaku                         
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Thippili                                                 Sathikkai 
 
 
 
 
 
 
 
 
 
 
 
                 Sathipatri                                                        Jirakam 
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KUKKIL CHOORANAM 
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EXTERNAL MEDICINES 
GINGELLY OIL 
Botanical Name : Sesamum indicum.Linn 
English Name : Sesame 
Family  : Papillonaceae 
Organoleptic Character 
Taste  : Inippu 
Potency : Veppam 
Division : Inippu 
 
  
 - 
  
  
 
Chemical Constituents:  
 Oleic and Linoleic Acid, Calcium, Phosphorus, Sodium Chloride, Lysine, 
Methionine, Free Fatty Acid, Oxalate and Aflatoxin B1 
Ref:http://www.indianjournals.com/ijor.aspx?target=ijor:anft&volume=8&issue 
&article=003 
Actions: 
 Demulcent 
 Laxative 
 Nutritive 
 Emollient 
   Ref: Indian Medicinal plants Compendium, Vol. – V, P – 104. 
 
KASUKATTI 
 
English Name : Catechu 
Organoleptic Character 
Taste  : Thuvarpu 
Potency : Thatpam 
Division : Karpu 
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Action: 
 Astringent. 
It cures, 
 Eczema 
 Diabetes 
 Menorrhogia 
 
THURUSU 
 
English Name : Copper Sulphate 
Organoleptic characters: 
Taste      : Thuvarppu 
 
 
-  
 
. 
It cures  
 Skindisease, 
 Indigestion, 
 Hepatomegaly, 
 Ascites, 
 Ulcer, 
 Eye disease, 
 Diarrhoea 
Actions: 
 Nutrient 
 Astringent 
 Antiseptic 
 Caustic 
 Emetic 
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KALIPPAKKU 
 
Botanical name :  Areca catechu 
English Name: Areca-nut  
Family   :  Arecaceae   
Organoleptic characters: 
Taste        : Thuvarppu 
Potency   : Vepam 
Division  : Kaarppu 
 
 
-  
 
. 
  -  
Chemical constituents: 
 Lupeol 
 Stigmasterol 
 Flavonoids 
 Carbohydrates 
[Ref. Book: Medicinal plants-Dr.M.Daniel] 
Actions:  
 Stimulant 
 Astringent 
 Toenifuge 
  
KADUKKAI 
 
Botanical Name :  Terminalia chebula. Retz 
English Name :  Chebulic Myrobalan, Ink nut 
Family  :  Combretaceae 
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Organoleptic Characters 
Taste  :  Thuvarppu, Inippu, Pulippukaarppu, Kaippu. 
Potency :  Veppam 
Division :  Kaarppu 
–
     
Chemical Constituents: 
The number of glycosides are isolated from Kadukkai, including the 
triterpenes arjunglucoside I, arjungenin, and the chebulosides I and II. Other 
constituents include acoumarin conjugated with gallic acids called chebulin, as well as 
other phenolic compounds including ellagic acid, 2,4-chebulyl-β-D-glucopyranose, 
chebulinic acid, gallic acid,ethyl gallate, punicalagin, terflavin A, terchebin, luteolin, 
and tannic acid.[ Chebulic acid is a phenolic acid compound isolated from the ripe 
fruits. Luteic acid can 0be isolated from the bark. T. chebula also contains terflavin B, 
a type of tannin while chebulinic acid is found in the fruits. 
                           Ref: Indian Herbal Pharmacopoeia. 
Action: 
 Laxative  
 astringent 
 Anthelmintic 
 Nervine 
 Expectorant 
 carminative  
 appetite stimulant 
 
 
KADUKKAI POO 
 
Botanical Name :  Terminalia chebula. Retz 
English Name :  Flower of Chebulic Myrobalan 
Family  :  Combretaceae 
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Organoleptic Characters 
Taste  :  Thuvarppu, Inippu, Pulippukaarppu, Kaippu. 
Potency :  Veppam 
Division :  Kaarppu 
Chemical Constituents: 
 Tannin 
 Chebulinic acid 
 Gallic acid 
Action: 
 Laxative  
 astringent 
 Anthelmintic 
 Nervine 
 Expectorant 
 carminative  
 appetite stimulant 
 
VEMBAADAM PATTAI 
 
Botanical name  :  Ventilago madraspatana 
English Name : Red Creeper 
Family   :  Rhamnaceae 
Chemical constituents: 
 Tannins 
Pharmacological activity: 
 Anti-Denaturation activity 
 Anti-oxidant activity 
 Anti-bacterial 
 Anti-Inflammation 
 Cytotoxic Activity (Anti-cancer) 
 -Int. J. Pharmacol. Bio. Sci., 5(2), 75-78, 2011. 
It cures, 
 Itching 
 Cutaneous eruption 
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SANDHANAM 
 
Botanical name  :  Santalum album 
English Name : Sandal wood 
Family   :  Santalaceae 
Organoleptic characters: 
Taste        :  Siruthuvarppu 
Potency   : Thatpam,Vepam 
Division  : Inippu,Kaarppu 
 
 
-  
 
 
 -  
Chemical constituents: 
 Santalol 
[Ref. Book: Medicinal plants-Dr.M.Daniel] 
Actions:  
 Alterative 
 Astringent 
 Diuretic 
 Diaphoretic 
 Stimulant 
 Disinfectant 
 Cooling 
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External Medicine 
 
Vembadam  pattai    Kali pakku 
 
 
 
 
 
 
 
 
 
 
 
Kasikatti                                             Kadukkai 
 
 
 
 
 
 
 
 
 
 
 
 
EXTERNAL MEDICINE 
 
 Page 57 
 
Thurusu                                                      Sandhanam 
 
 
   Nallenai      Thuvara Ennai 
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MATERIALS AND METHODS 
STANDARD OPERATING PROCEDURE: 
COLLECTION OF RAW DRUGS: 
  The required raw drugs for the preparation of the trial medicines were 
procured from a well reputed country raw drug shop. 
RAW DRUGS IDENTIFICATION AND AUTHENTICATION: 
The mineral raw drugs were identified and authenticated by Smt.R.Shakila, 
RO chemistry, Siddha Central research Institute, Arumbakkam, Chennai-106. The 
Herbal raw drugs were identified and authenticated by Dr.D.Aravind M.D(s), 
Assistant professor, Dept. of Botany, National Institute of Siddha, chennai-47. After 
that the raw drugs were purified as per siddha literature then the trial drugs prepared 
in Gunapadam laboratory of National Institute of Siddha. 
INTERNAL DRUG:  
KUKKIL CHOORANAM (Ingredients) 
Suthi seitha kukkil (Shorea robusta)              - 2 Palam (70gm)                                                                                   
Suthi seitha  parangipattai(Smilax china) - 2 Palam(70gm)                                                                                   
Suthi seithagandhagam(sulphur)        - ½Palam(17.5gm)  
Milagu(Piper nigrum)   - 1Palam(35gm) 
Thippili(Piper longum)                               - 1Palam(35gm) 
Kurosani omam(Hyocyamus niger)                - 1Palam(35gm) 
 Jathikkai(Myristica fragrans)                        - 1Palam(35gm) 
Jathipathiri(Myristicafragrans)                   - 1Palam(35gm) 
Thanrikkai thool(Terminalia bellirica)          - 1Palam(35gm) 
Seeragam(Cuminum cyminum)                      - 1Palam(35gm) 
Chitrarathai(Alpinia officinarum)                  - 1Palam(35gm) 
Nellimulli(Phyllanthus emblica) -1Palam(35gm)     
METHOD OF PURIFICATION OF RAW DRUGS: 
Purification of Kukkil: 
 The Kukkil is boiled in tender coconut water. 
                       [Ref: Sarakugalin  suthee  muraigal  page  4] 
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Purification of Parangi pattai: 
It is dried, powdered and then boiled in Steam of milk (Pittaviyal). 
[Ref:Sarakugalin  suthee  muraigal  page  11] 
Purification of Ganthagam: 
Sulphur is placed in an iron spoon. A small quantity of cow’s butter is added 
and the spoon is heated till the butter melts; this mixture is immersed in inclined 
position in cow’s milk. This procedure is repeated for 30 times to get purified sulphur. 
Each time, fresh milk is to be used. 
             (Ref: Siddha Materia Medica (Mineral and animal kingdom) Page No: 253) 
Purification of Milagu:  
Soak   in  butter  milk  for  a  period  of one saamam (3 hours)  then  allow  it  
to  dry.  
[Ref: Sikicha Rathina Deepam Ennum Vaithiya Nool page 28]                   
Purification of Thippili: 
Soak in juiceof Lime then allow it to dry.   
 [Ref: Sarakugalin sutheemuraigal page 7] 
Purification of Kurosani omam 
Put it into sand and mix well then remove the outer covering. 
[Ref:Sarakugalin  suthee  muraigal  page  5] 
Purification of Jaathikkai: 
Remove the outer cover, cut into small pieces and dry it inshadow. 
[Ref: Sighitcha Rathan Deepam Ennum Vaithiya Nool, Page: 29] 
Purification of Jaathipathiri: 
Remove the flowerlets and dry in the shadow.  
[Ref:Sighitcha Rathan DeepamEnnum Vaithiya Nool, Page: 29] 
Purification of Thandrikkai: 
Remove the nut and use the outer covering of the drug. 
[Ref: Sarakugalin  suthee  muraigal  page  7] 
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Purification of Chitrarathai: 
Cut the rhizome into pieces and dry it in shadow.                     
[Ref: Sikicha Rathina Deepam Ennum Vaithiya Nool, page 35]
 
Purification of Narseeragam: 
Dry it shadow for 6hours and fry well. 
 [Ref: Sarakugalin  suthee  muraigal  page : 6]   
Purification of Nellimulli:
 
Remove the nut and use the fleshy part of the drug. 
[Ref: Sarakugalin suthee muraigal Page: 9]      
 METHOD OF PREPARATION: 
Purified raw drugs were dried, pulverized in mortar and filtered with cotton cloth 
and stored in a container. 
EXTERNAL MEDICINE:  
THUVARA ENNAI (Ingredients)
 
Gingelly oil                                                     - 1 padi(1.4 lit) 
Kaasukatti(Catechu)    - 1varaagan(3.5 gm) 
Thurusu(Copper sulphate)                              -  1varaagan (3.5gm)  
Kalipaku(Areca catechu)                                - 1varaagan (3.5gm)  
Kadukkai(Terminalia chebula)  - 1varaagan (3.5gm) 
Kadukkai poo(Terminalia chebula)   - 1varaagan (3.5gm) 
Vembaadam pattai(Ventilago madraspatana)-  1varaagan (3.5gm)   
Santhana thool(Santalum album)  - 1varaagan (3.5gm)   
METHOD OF PREPARATION:  
All ingredients are powdered make it into paste and mixed with oil and then 
boiled till it attained the consistency. 
DRUG STORAGE: 
 The trial drug Kukkil chooranam is stored in a clean and dry glass bottles and 
Thuvara Ennai is stored in a clean and dry narrow mouthed bottles. 
DISPENSING: 
The Powder is given in packet. Oil is given in pet bottles.  
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PRECLINICAL STUDY:  
CHEMICAL EVALUATION 
  Experimental procedure:  
5 g of Kukkil Chooranam was taken in a 250 ml of clean beaker and 50ml of 
distilled water was added to it. Then it was boiled well for about 10 min. Then it is 
allowed to cool and filtered in a 100 ml volumetric flask and made up to 100 ml with 
distilled water. This preparation is used for the qualitative analysis of acidic/ basic 
radicals and biochemical constituents in it. 
Preparation of extract:  
5gm of Kukkil Chooranamis weighed accurately and placed in a 250ml clean 
beaker and 50ml of distilled water was added with it. Then it was boiled well for 
about 10 minutes. Then it was allowed to cool and filtered in a 100ml volumetric 
flask and made up to 100ml with distilled water.The bio-chemical analysis of Kukkil 
Chooranamwas done at Biochemistry lab, National Institute of siddha, Chennai-47. 
Preliminary test forCopper, Sodium, Silicate and Carbonate: 
 Test for Silicate: 
a.  A little (500mg) of the sample is shaken well with distilled water. 
b.  A little(500mg) of the sample is shaken well with con. HCl/Con. H2So4. 
 Action of Heat: A small amount (500mg) of the sample is taken in a dry test 
tube and heated gently at first and then strong. 
 Action of Heat: A small amount (500mg) of the sample is taken in a dry test 
tube and heated gently at first and then strong. 
 Flame Test: A small amount (500mg) of the sample is made into a paste 
with con. HCl in a watch glass and introduced into non-luminous part of the 
Bunsen flame. 
 Ash Test: A filter paper is soaked into a mixture of sample and dil. cobalt 
nitrate solution and introduced into the Bunsen flame and ignited. 
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Test For Acid Radicals 
 Test For Sulphate:2ml of the above prepared extract was taken in a test 
tube and 2ml of 4% dil. ammonium oxalate solution was added. 
 Test For Chloride: 2ml of the above prepared extracts was added with 2ml 
of dil-HNO3 until the effervescence ceases off. Then 2 ml of silver nitrate 
solution was added. 
 Test For Phosphate: 2ml of the extract was treated with 2ml of con.HNo3 
and 2ml of dil. ammonium molybdate solution.   
 Test For Carbonate: 2ml of the extract was treated with 2ml dil. 
magnesium sulphate solution 
 Test For Nitrate:1gm of the substance was heated with copper turning and 
concentrated H2SO4 and viewed the test tube vertically down. 
 Test For Sulphide: 1gm of the substance was treated with 2ml of con. HCL 
 Test For Fluoride & Oxalate: 2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride solution and heated. 
 Test For Nitrite: 3drops of the extract was placed on a filter paper, on that-2 
drops of dil.acetic acid and 2 drops of dil. Benzidine solution were placed. 
Test For Basic Radicals 
 Test For Lead: 2ml of the extract was added with 2ml of dil. potassium 
iodine solution. 
 Test For Copper: One pinch (50mg) of substance was made into paste with 
con. HCl in a watch glass and introduced into the non-luminous part of the 
flame. 
 Test For Aluminium: In the 2ml of extract dil. sodium hydroxide was added 
in 5 drops to excess. 
 Test For Iron: 
a.To the 2ml of extract add 2ml of dil. ammonium solution 
b. To the 2ml of extract 2ml  thiocyanate solution and 2ml  of con HNo3 is added 
 Test For Zinc: In 2ml of the extract dil.sodium hydroxide solution was 
added in 5 drops to excess and dil.ammonium chloride was added.  
 Test For Calcium: 2ml of the extract was added with 2ml of 4% 
dil.ammonium oxalate solution  
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 Test For Magnesium: In 2ml of extract dil.sodium hydroxide solution was 
added in drops toexcess. 
 Test For Ammonium:In 2ml of extract 1 ml of Nessler's reagent and excess 
of dil. sodium hydroxide solution were added. 
 Test For Potassium:A pinch (25mg) of substance  was treated  with 2ml of 
dil. sodium nitrite solution and then treated with 2ml of dil. cobalt nitrate in 
30% dil. glacial acetic acid. 
 Test For Sodium: 2 pinches (50mg) of the substance was made into paste 
by using HCl and introduced into the blue flame of Bunsen burner. 
 Test For Mercury: 2ml of the extract was treated with 2ml of dil. sodium 
hydroxide solution.  
 Test For Arsenic: 2ml of the extract was treated with 2ml of dil. sodium 
hydroxide solution. 
Other constituents 
 Test For Starch : 2ml of extract was treated with weak dil. iodine solution  
 Test For Reducing Sugar: 5ml of Benedict's qualitative solution was taken in 
a test tube and allowed to boil for 2 minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes.  
 Test For The Alkaloids: 
a) 2ml  of the extract is treated with 2ml of dil. potassium iodide solution.    
b) 2ml of the extract is treated with 2ml of dil.picric acid. 
 Test For Tannic Acid: 2ml of extract was treated with 2ml of dil. ferric 
chloride solution 
 Test For Unsaturated Compound: In the 2ml of extract 2ml of dil. 
Potassium permanganate solution was added.  
 Test For Amino Acid: 2 drops of the extract was placed on a filter paper 
and dried well, and then 20ml of Burette reagent was added in it. 
 
 
 
 
MATERIALS AND METHODS 
 
 Page 64 
 
TOXICITYSTUDIESOFKUKKIL CHOORANAM 
To evaluate the safety profile of Kukkil chooranam short term and long term 
toxicity study carried out as followed. The principles of laboratory animal care were 
followed and the Institutional Animal Ethical Committee approved the use of 
animals and the study design. IAEC registered and approval number:  
(IAEC).(NIS/IAEC/III/06/29092016dated29.09.2016) for Short term toxicity study 
and Long term toxicity study 
 
ExperimentalAnimals: 
Species               : Wistar albino Rats 
Sex      : Male and Female  
Age/weight  at start of test  : 6 weeks/140-160g b.wt 
Acclimatization Period  : 7 days prior to dosing 
Housing    : Polypropylene cages with  bedding with  
                                                                        husk 
Husbandry    : 12-h light/12-h dark cycle/ Room  
                                                                         temperature 22°C±3°C and relative  
humidity30–70% 
Feed and Water   :  Rodent pelleted feed RO purified water  
                                                                        adlibitum   
Identification   : Animals will be kept in Polypropylene  
cages and numbered  
Experimentation Details of Short term Toxicity Study: 
Groups/Treatment regimen  : Grouped by randomisation 
Test Guideline    : WHO 
Length of exposure to test substance : 1 day 
No of Animals    : 5 Female+ 5 Male / group 
Control group    : Vehicle(honey) 
Test groups    :  Kukkil Chooranam2000 mg/kg.b.wt  
 
The wistar albino rats of both sex weighing 150-200g will be obtained from 
authorized animal breeders of animal laboratory inTANUVAS, Madavaram, Chennai 
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and stocked in animal house atNational Institute of Siddha, Chennai.  Animals will be 
house in cage at 22°C±3°C andrelative humidity 30–70% and have free access to 
standard rat pellet diet (Sai Meera Foods Pvt. Ltd., Bangalore). The animals will be 
dosed with Kukkil chooranam by oral for one day and monitored for behavioural 
parameters for the first 4 hours after drug administration. Body weight of the animal 
will be monitored at weekly intervals. The animals that the die within this period will 
be subjected to necropsy. Remaining animals will be weighed and sacrificed under  
the injuction of Pentathal Sodium on the 15
th
day of the Study period.The 
toxicologicaleffectwereassessedonthe basisofmortality. 
PreparationofTestDrugDoses: 
Groups No. of Rat 
Group I:  Vehicle control (honey) 10 (5M+5F) 
Group II: test drug (KC)- 2000 mg/kg b.wt 10 (5M+5F) 
                 *KC- Kukkilchooranam 
Route of administration 
Oral route were selected because it is the normal route of clinical administration. 
Administration of Dose 
The animals were kept in fasting (only food was with held) for 12 hrs and 
weighed prior to dosing. Three animals were used for each step. A single dose of the 
solution (2000mg/kg) was consecutively administered by oral gavage using 
intubation cannula. Food was with held for another 4 hrs after dosing and 
administration of drug. As per the guideline the starting dose level was taken as 
2000mg/kg body weight. 
Observations: 
Observations were made and recorded systematically and continuously 
observed after the substance administration as per the guidelines.  
 ½ hour, 1 hour, 2 hour, 4 hour and upto 24 hours observation 
 All rats will be observed twice daily on week days for 14 days 
 Body weight per weekly one times 
 Feed intake per day 
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Cage side observation  
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, pilo erection,Grooming, Gripping,Touch Response, Motor Activity, 
Tremors,Convulsions, Muscle Spasm,Catatonia, Muscle relaxant, Hypnosis 
Analgesia, Lacrimation, Exophthalmos, Diarrhea,Writhing,  Respiration, Mortality 
Necropsy: 
Necropsy includes gross examinations of the external surface of the body, all 
orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eye, lungs, 
heart, spleen, liver, kidneys, adrenals, uterus, of all animals. 
Experimentation Details of Long term Toxicity Study: 
Experimental Animals: 
Species               : Wistar Albino Rats 
Sex      : Male and Female 
Age/weight  at start of test  : 6 weeks/140-160g b.wt 
Acclimatization Period  : 7 days prior to dosing 
Housing    : Polypropylene cages with  bedding with   
         husk  
Husbandry    : 12-h light/12-h dark cycle/ 
       Room temperature 22°C±3°C and 
       relative humidity 30–70% 
Feed and Water   : Rodent pelleted feed 
       RO purified water ad libitum 
Identification   : Animals will be kept in 
       polypropylene cages and 
       numbered 
Experimentation Details of Acute Toxicity Study: 
Groups/Treatment regimen  : Grouped by randomisation 
Test Guideline    : WHO 
Length of exposure to test substance : 90 days 
No of Animals    : 10 Female+10 Male / group 
Control group    : Vehicle(honey) 
Test groups    : Kukkil Chooranam (Low dose, Mid dose,  
High dose)                                                  
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The 80 Wistar albino rats of both sex selected randomly. The animals were 
divided into four groups. Each groups consist at 20 animals. First group treated as 
vehicle control and second, third and fourth groups were treated with Kukkil 
chooranam Low dose (180 mg), Mid dose (900 mg) and High dose (1800 mg) 
respectively. The animals were dosed with Kukkil chooranam by oral for 90 days and 
is monitored for behavioural parameters for the first 4 hours after drug administration. 
Body weight of the animal was be monitored at weekly intervals. The animals that die 
within this period was be subjected to necropsy. Remaining animals was be weighed 
and sacrificed under  the injuction of Pentathal Sodium on the on the 91
st  
day of the 
study. Blood will be collected from the anesthetized animals from Abdominal aorta. 
and the following investigations like Haematology, Biochemical analysis and 
Histopathology are done. 
They above dose were fixed from the result of Short term toxicity study 
 
Groups No. of Rats 
Group I:  Vehicle control (honey) 20(10M+10F) 
GroupII:Test drug (KC)- low dose (180mg/kg b.wt) 20(10M + 10F) 
GroupIII: Test drug(KC) - Mid dose (900mg/kg.b.wt) 20(10M +10F) 
GroupIV:Test drug(KC) High dose (1800 mg/kg b.wt) 20(10M +10F) 
*KC- Kukkil chooranam 
Preparation and administration of dose: 
Kukkil Chooranamwas dissolved in honey to obtain concentrations of 
1800mg/ml. It was administered to animals at the dose levels of 180mg/kg b.wt, 
900mg/kg b.wtand1800mg/kg b.wt. The test substance solutions were freshly prepared 
every two days once for 90days. The control animals were administered with honey as 
vehicle. Administration was given by oral, once daily for 90 consecutive days.  
Observations: 
Experimental animals were kept under observation throughout the course of study 
For the following 
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 All rats will be observed twice daily on week days for 90 days 
 Body weight per weekly one times 
 Feed intake per day 
Cage side observation   
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, pilo erection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis 
Analgesia, Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality. 
Gross necropsy: 
Gross necropsy includes examinations of the external surface of the body, all 
orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eye, lungs, 
heart, spleen, liver, kidneys, adrenals, uterus, of all animals. 
Laboratory Investigations: 
On the91
st 
day,the animalswerefastedovernight,thenanesthetizedto 
collectblood samplesfromtheabdominalaorta intwotubes: onewith  EDTA 
forhematologicalparameters,anotheronewithoutanyanticoagulantandwascentrifugedat
4000rpmat4°Cfor10minutestoobtaintheserumforbiochemicalparameters. 
HematologicalInvestigations: 
Blood samples of control and experimental rats were analyzed for hemoglobin 
(Hb), total red blood corpuscles (RBC), white blood corpuscles (WBC) count,  Mean 
corpuscular volume (MCV), Mean corpuscular hemoglobin(MCH) were calculated. 
Biochemical Investigations: 
Serum samples of control and experimental rats were analysed for Bilirubin, 
Uric Acid, Creatinine, Triglyceride, Total Cholesterol, HDL, LDL, VLDL, using 
standard methods. Activities of glutamate oxalo acetate transaminase/Aspartate 
amino transferase (GOT/AST) and glutamate pyruvate transaminase/ Alanine amino 
transferase (GPT/ALT) were estimated as per the colorimetric procedure. 
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Necropsy: 
All the animals were sacrificed on the 91
st 
day. Necropsy of all animals was 
carried out and the weights of the organs including liver, kidneys, spleen, brain, heart, 
lungs and stomach were recorded. 
Histopathology: 
The organs included liver, kidneys, spleen, brain, heart, lungs and stomach of 
the animals were preserved, and they were subjected to histopathological 
examination. 
Histopathological investigation of the vital organs was done. The organ 
pieces(35µm thick) of the three different (low, mid, high) dose level was preserved 
and was fixed in 10% formalin for 24 hand was hed in running water. Samples were 
dehydrated in an auto technic on and then cleared in benzene to remove absolute 
alcohol. Embedding was done bypassing the cleared samples through three cups 
containing molten paraffin at 50
o
C and then in a cubical block of paraffin made by the 
“L” molds. It was followed by micro to me and the slides were stained with 
Haematoxylin-eosin. 
Statistical analysis: 
Findings   such   as body weight   changes,   food consumption,   water   
intake, hematology and biochemical analysis were subjected to One-way 
ANOVADunnet’s test using a computer software program followed by D Graph Pad 
Instat-3.  
CLINICAL STUDY: 
STUDY DESIGN:  
STUDY TYPE               :  An open clinical trail 
STUDY PLACE            :  OPD and IPD of Ayothidoss Pandithar Hospital,  
     National Institute of Siddha, 
  Tambaram Sanatorium, Chennai - 47. 
STUDY PERIOD          :  18 Months 
SAMPLE SIZE              :  40 patients (Both IPD & OPD) 
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SUBJECT SELECTION: 
Patients reporting with symptoms of inclusion criteria will be subjected to 
screening test and documentation. 
INCLUSION CRITERIA 
 Age : 20-60 years 
 Sex : Both male and female 
 Presence of ulcers with varicose veins 
 With or without Pain, Itching, Edema, Fibrinous exudates in the lesions 
 Hyper pigmentation 
 Eczema around the ulcer 
 Willing to give specimen of blood for the investigation.  
 Permit to take photograph. 
 Willing to participate in trial and signing consent by fulfilling the condition 
of   Proforma. 
EXCLUSION CRITERIA 
 H/o of Diabetes Mellitus. 
 H/o of Hansen’s disease. 
 H/o of  Diabetic ulcer 
 H/o of Gangrene 
 H/o of Tuberculosis ulcer  
 H/o of any other systemic illness. 
WITHDRAWAL CRITERIA 
 Intolerance to the drug and development of any serious adverse effect during  
drug trial. 
 Poor patient compliance & defaulters 
 Patient unwilling to continue the course of clinical Study. 
 Occurrence of any other systemic illness 
TESTS AND ASSESMENTS: 
            1. Clinical assessment  
2. Siddha system assessment 
3. Routine investigations 
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1. CLINICAL ASSESMENT: 
 Presence of ulcers with varicose veins 
 With or without Pain, Itching, Edema, Fibrinous exudates in the lesions 
 Hyper pigmentation 
 Eczema around the ulcer 
1. INVESTIGATIONS BASED ON SIDDHA SYSTEM: 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8.Moothiram               ● Neerkkuri:  ● Neikkuri: 
1. INVESTIGATION: 
BLOOD 
 Hb 
 Total WBC Count 
 DC         
 Polymorphs 
 Lymphocytes  
 Eosinophils 
 Monocytes  
 Basophils  
 Total RBC count  
 ESR -         ½ Hr:                   1 Hr: 
 Blood sugar Fasting:  PP: 
 Serum cholesterol 
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URINE 
 Albumin 
 Sugar(F)                          (PP) 
 Deposits 
RENAL FUNCTION TESTS 
             Blood Urea 
             Serum Creatinine 
             Uric acid 
LIVER FUNCTION TESTS 
              Serum total bilirubin 
              Direct bilirubin 
              Indirect bilirubin 
              Serum Alkaline phosphatases 
              SGOT 
SGPT 
 
DATA COLLECTION: 
Required information were collected from each patient by using the following forms 
FORMS:  
FORM I            Screening and selection Proforma 
FORM II           Clinical assessment Proforma 
FORM III          Laboratory investigation Proforma  
FORM IV          Patient information sheet 
FORM V  Consent form 
FORM VI  Withdrawal form/Pharmacovigilance 
FORM VII  Dietary Advice form 
STUDY ENROLLMENT: 
 Patients reporting at the OPD with clinical feature of chronic ulcer, oedema, 
skin hyperpigmentation, fibrinous exudate, itching and eczema around the 
ulcer were chosen for enrolment based on the inclusion and exclusion criteria. 
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 The enrolled patients were informed about the study, trial drug, possible 
outcomes and the objectives of the study in the language and terms 
understandable to them and getting consent in the Informed Consent form 
(Form VI). 
 Complete clinical history, complaints and duration, examination findings-- all 
would be recorded in the prescribed Performa’s. 
 Screening Form- I will be filled up, Form –II and Form –III were used for 
recording the patients, history, clinical examination of symptoms and signs 
and laboratory investigations respectively. If there is any abnormal laboratory 
reports obtained then excluded from this study. Patients would be advised to 
take the trial drug and appropriate dietary advice (Form VII)   would be given 
according to the patients, perfect understanding.  
CONDUCT OF THE STUDY: 
The day before the treatment Purgation were given with Agasthiyar Kuzhambu 
200mg in the early morning in empty stomach with Sangankuppi juice for balancing 
the deranged humours. Then the trial drugs “KUKKIL CHOORANAM” (Internal) an 
“THUVARA ENNAI” (External) were given for 48 days.   
OPD patients are requested to visit the hospital once in 7 days. In each and 
every visit clinical assessment and prognosis were recorded in the presence of faculty 
members. For IPD patients the clinical assessment and prognosis were recorded daily.  
Laboratory investigations were done before and after the trial. For IPD patients, 
who are not in a position to stay in the hospital for a long time, are advised to attend 
the OPD for further follow-up. At the end of the trial, the patients are advised to visit 
the OPD for follow-up for any recurrence. Defaulters were withdrawn from the study 
with fresh case being inducted. 
 
ADVERSE/SERIOUS EFFECTS MANAGEMENT: 
 In this study, no adverse reactions were observed during the course of treatment. 
DATA ANALYSIS: 
After enrolling the patients in the study, a separate file for each patient was 
maintained and all forms was kept in the file. Study No. and patient’s No. was entered 
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on the top of the file for easy identification. Whenever the patients visit OPD during 
the study period, necessary entries was made at the assessment forms.  
The screening forms were filled separately. 
All forms were further scrutinized by Senior Research Officer (Statistics) for 
logical errors and incompleteness of data to avoid any bias. No modification in the 
results is permitted for unbiased reports. 
OUTCOME: 
Improvement assessed by following assessment: 
1. The Outcome of the treatment will be observed by Venous clinical severity 
score (VCSS) before and after treatment. 
 
VENOUS CLINICAL SEVERITY SCORE      
ATTRIBUTE ABSENT=0        MILD=1    MODERATE=2          SEVERE=3 
 
PAIN 
 
None 
 
Occasional, not 
Restricting activity 
or Requiring 
pain Medication 
 
Daily moderate activity 
Limitation; occasional 
Pain medication 
 
Daily, severe limiting 
Activities or requiring 
Regular use of pain 
Medications 
 
VARICOSE 
VEINS 
 
None 
 
Few scattered 
 
Multiple; great 
Saphenous 
Veins, confined to calf 
And thigh 
 
Extensive; thigh and calf or 
Great and small saphenous 
Distribution 
 
VENOUS EDEMA 
 
None 
 
Evening ankle 
swelling 
Only 
 
Afternoon swelling, 
Above ankle 
 
Morning swelling above 
Ankle and requiring 
Activity change, elevation 
 
SKIN 
PIGMENTATION 
 
None 
 
Diffuse, but 
limited in 
Area and old 
(brown) 
 
Diffuse over most of 
Gaiter distribution 
(lower 
Third) or recent 
Pigmentation (purple) 
 
Wider distribution (above 
Lower third) plus recent 
Pigmentation 
 
 
 
INFLAMMATION 
 
None 
 
Mild cellulitis, 
limited 
To marginal area 
Around ulcer 
 
Moderate cellulitis, 
Involves most of (lower 
third) 
 
Severe cellulitis (lower 
Third and above) 
Or significant 
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INDURATION 
 
None 
 
Focal, 
circummalleolar 
 
Medial or lateral, less 
Than lower third of leg 
 
Entire lower third of leg or 
more 
 
NUMBER OF 
ACTIVE 
ULCERS 
 
0 
 
1 
 
2 
 
>2 
 
ACTIVE ULCER 
DURATION 
 
None 
 
<3 months 
 
>3 months, <1year 
 
Not healed>1 year 
 
ACTIVE ULCER 
DIAMETER 
 
None 
 
<2 
 
2-6 
 
>6 
 
COMPRESSION 
THERAPY 
 
Not used or 
Patient not 
Compliant 
 
Intermittant use of 
Stockings 
 
Wears elastic stocking 
Most days 
 
Full compliance, 
Stockings + elevation 
 
OUTCOME: 
 GOOD – Complete healing of ulcer and 75-100% reduction of VCSS Score 
 MODERATE – Partial healing of ulcer and 50-75% reduction in VCSS Score 
 MILD – Slight reduction of ulcer and 25-50% reduction in VCSS Score 
 POOR – No reduction of ulcer and 0-25% VCSS Score 
 
 
 
 
 
  
 
 
OBSERVATION AND 
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QUALITATIVE ANALYSIS 
PHYSICO-CHEMICAL ANALYSIS 
Table-1: Colour, nature of Kukkil Chooranam 
 
Table-2: Test for Basic radicals 
S.no Procedures Kukkil Chooranam 
 
1. Test for Ammonium  
- 
2. Test for Sodium - 
 
3. Test for Magnesium - 
 
4. Test for Aluminium - 
 
5. Test for Potassium + 
 
6. Test for Calcium + 
 
7. Test for Ferrous iron  
+ =+ 
8. Test for Copper  
- 
9. Test for Zinc  
- 
10. Test for Arsenic - 
 
11. Test for Mercury - 
 
12. Test for Lead - 
 
 
 
S.no Parameters Results Method of Testing 
 
1. Colour Yellowish green By visual 
 
2. Odour Odour(Omam Smell) Olfactory examination 
 
 
3. Solublity  Soluble in honey 
 Insoluble in water 
Qualitative 
 
 
4. Nature Powter By visual 
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Inference 
Bio-chemical analysis for basic radicals reveals that Kukil Chooranam 
contains Potassium, Calcium and Iron. 
 
Table-3: Test for Acidic radicals 
S.no Procedures Kukkil Chooranam  
 
1. Test for Sulphate  
- 
2. Test for Chloride + 
 
3. Test for Phosphate + 
 
4. Test for Flouride&Oxalate  
- 
5. Test for Nitrate _ 
 
Table-4: Test for Acidic radicals 
S.no Procedures Kukkil Chooranam 
 
1. Test for Starch + 
 
2. Test for Reducing sugar _ 
 
3. Test for Alkaloids + 
 
4. Test for Amino acids _ 
 
5. Test for Tannic acids + 
 
6. Test for type of compounds  
No Change 
 
Inference 
 Bio-chemical analysis for acid radicals reveals that Kukil Chooranam contains 
Chloride, Starch, Alkaloids, Tannic acids 
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Toxicity study Results of Kukkil Chooranam 
Table: 5 Dose finding experiment and its behavioural Signs of Toxicity 
No Dose 
Mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 
 
 
1. Control + - - + + + - - - - - - - - - - - - + - 
 
2. 2000 + - - + + + - - - - - - - - - - - - + - 
 
 
1.Aletness 2.Aggressiveness 3.pilo erection 4.Grooming 5.Gripping 6.Touch 
Response 7. Motor Activity 8. Tremors 9.Convulsions 10.Muscle Spasm 11.Catatonia 
12.Muscle relaxant 13.Hypnosis 14.Analgesia 15.Lacrimation 16.Exophthalmos 
17.Diarrhoea 18.Writhing 19. Respiration 20.Mortality 
+ Presence of Activity  
- Absence of Activity 
All the data were summarized in the form of table revealed no abnormal signs and 
behavioural changes in rats at the dose of 2000 mg/kg body weight administered 
orally 
Short term  Toxicity study 
In short term toxicity study, the test drug atKukkil Chooranam for single 
dose(2000mg/kg b.wt) was administered. 
There was no mortality or signs of toxicity observed after dosing Kukkil 
Chooranam 2000mg/kg body weight during the study period of 14 days. This indicate 
that the LD50 of Kukkil Chooranam is more then 2000mg/kg b.wt. 
There was no changes in skin and fur, eyes and mucous membranes of all 
animals.  The eating ,drinking habit, sleep pattern, locomotion were normal in all 
animals and no changes in body weight as compared to control group. 
At the end of the 14 
th
 day necropsy was done and there was no abnormality 
seen in test groups as compared to control group during the examination. 
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Long term Toxicity study 
Table 6:Effect of Kukkil Chooranam on Biochemical parameters 
 
Dose (mg/kg) 
 
 
Control 
 
LD 
 
MD 
 
HD 
 
Total cholesterol(mg/dl) 
 
111.26±1.16 
 
148.9±22.3 
 
151.95±19.8 
 
148.2±20.8 
 
 
HDL(mg/dl) 
 
60.5±4.08 
 
 
69.1±12.8 
 
63.16±5.40 
 
65±10.8 
 
LDL(mg/dl) 
 
31.16±5.03 
 
60±20.8 
 
60.16±13.6 
 
63±12.39 
 
 
VLDL(mg/dl) 
 
16.43±2.72 
 
19.8±6.2 
 
23.26±5.51 
 
17.95±6.24 
 
 
 Triglycerides(mg/dl) 
 
49.66±2.33 
 
42.6±16.1 
 
42.08±10.18 
 
 46.41±9.1 
 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
Figure:1 
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Table 7:Food (g/day) intake of albino rats exposed to Kukkil 
Chooranam 
Dose 
(mg/kg/day) 
 
 
Control 
 
LD 
 
MD 
 
HD 
1
st
 day  
5.54±0.21 
 
 
6.11±0.21 
 
 
5.59±0.25 
 
6.2±0.15 
 
15 
th
 day 
 
 
6.3±0.18 
 
6.4±0.21 
 
6.7±0.27 
 
7.27±0.27 
 
30 
th
 day 
 
 
6.7±0.27 
 
7.07±0.17 
 
6.65±0.18 
 
7.45±0.24 
 
45 
th
 day 
 
 
7.07±0.17 
 
7.08±0.18 
 
7.07±0.17 
 
7.45±0.25 
 
60 
th
 day 
 
 
7.07±0.17 
 
7.27±0.27 
 
7.37±0.24 
 
7.45±0.25 
75 
th
 day 
 
 
7.27±0.27 
 
7.37±0.24 
 
7.60±0.28 
 
7.63±0.25 
90 
th
 day 
 
 
7.60±0.28 
 
7.63±0.25 
 
7.95±0.11 
 
7.75±0.13 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
Figure:2 
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Table 8:Water (ml/day) intake of albino rats exposed to Kukil 
Chooranam 
Dose 
(mg/kg/day) 
 
 
Control 
 
LD 
 
MD 
 
HD 
1
st
 day 
(ml/rat) 
 
9.15±0.13 
 
8.13±0.12 
 
 
9.15±0.12 
 
9.20±0.15 
 
15 
th
 day 
(ml/rat) 
 
9.52±0.21 
 
8.13±0.12 
 
8.13±0.12 
 
8.13±0.12 
 
30 
th
 day 
(ml/rat) 
 
8.13±0.12 
 
8.13±0.12 
 
9.52±0.21 
 
8.13±0.12 
 
45 
th
 day 
(ml/rat) 
 
9.96±0.11 
 
9.25±0.17 
 
9.15±0.12 
 
8.13±0.12 
 
60 
th
 day 
(ml/rat) 
 
9.96±0.11 
 
9.52±0.21 
 
9.96±0.11 
 
9.52±0.21 
75 
th
 day 
(ml/rat) 
 
9.96±0.11 
 
9.96±0.11 
 
10.30±0.13 
 
9.96±0.11 
 
90 
th
 day 
(ml/rat) 
 
9.96±0.11 
 
10.30±0.13 
 
9.96±0.11 
 
9.96±0.11 
 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
Figure:3 
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Table:9Body weight (g) changes of albino rats (female) exposed to 
                                                  Kukil Chooranam 
Dose 
(mg/kg/day) 
 
 
Control 
 
LD 
 
MD 
 
HD 
 
1
st
 day 
 
134.16±4.21 
 
 
138.12±3.50 
 
140.2±2.13 
 
138.14±2.46 
 
15 
th
 day 
 
 
164.16±4.21 
 
158.45±2.16 
 
162.36±5.07 
 
157.25±1.67 
 
30 
th
 day 
 
 
190.83±6.14 
 
189.16±6.23 
 
192.12±4.21 
 
189.25±5.26 
 
45 
th
 day 
 
 
209.16±5.07 
 
206±4.21 
 
210.2±6.30 
 
207±3.16 
 
60 
th
 day 
 
 
235.83±4.21 
 
237.38±6.14 
 
240.24±6.14 
 
239.68±4.21 
 
75 
th
 day 
 
 
270.83±6.30 
 
272.5±5.02 
 
278.8±2.36 
 
276.26±6.24 
 
90 
th
 day 
 
 
315.5±6.44 
 
318.24±6.12 
 
320.6±5.07 
 
318.28±1.36 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
Figure:4 
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Table:10 Body weight (g) changes of albino rats (male) exposed to 
Kukil Chooranam 
Dose 
(mg/kg/day) 
 
 
Control 
 
    LD 
 
    MD 
 
      HD 
 
1
st
 day 
 
139.33±4.13 
 
 
142.24±4.12 
 
152.16±2.45 
 
148.16±6.27 
 
15 
th
 day 
 
 
173±5.79 
 
174.12±5.26 
 
178.16±5.79 
 
176±5.12 
 
30 
th
 day 
 
 
203±5.79 
 
204.16±4.23 
 
202.18±9.12 
 
206.33±2.4 
 
45 
th
 day 
 
 
236.16±9.24 
 
239±9.24 
 
239.23±8.28 
 
240.25±9.24 
 
60 
th
 day 
 
 
288.66±9.24 
 
292.25±6.23 
 
297.26±5.20 
 
296.67±2.67 
 
75 
th
 day 
 
 
319.5±8.50 
 
 
320.1±9.28 
 
326.5±4.13 
 
324.13±4.12 
 
90 
th
 day 
 
 
359.5±9.71 
 
 
352.18±6.58 
 
348.16±7.02 
 
347.4±8.50 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
Figure:5 
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Table:11Effect of Kukil Chooranam on Haematological Parameters 
Parameter Control LD MD HD 
 
 
RBC(×10
6
µl) 
 
4.08±0.09 
 
6.57±1.17 
 
6.51±1.15 
 
5.98±0.4 
 
WBC(×10
3
µl) 
 
8.93±0.48 
 
10.01±2.7 
 
9.91±2.1 
 
9.84±1.7 
 
PLT(×10
3
µl) 
 
792.8±93.33 
 
819.16±134.5 
 
710.41±73.4 
 
705.75±123.08 
 
HGB(g/dl) 
 
12.5±0.74 
 
13.27±1.4 
 
12.95±2.02 
 
13.6±1.5 
 
Neutrophils 10
3
/mm
3
 
 
2.01±0.47 
 
2.78±0.71 
 
2.65±0.84 
 
2.30±0.67 
 
Lymphocyte(%) 
 
76.4±1.52 
 
78.2±9.88 
 
72.59±11.1 
 
74.4±10.2 
 
Monocyte(%) 
 
3.18±0.11 
 
2.69±0.61 
 
3.41±1.09 
 
3.6±0.95 
 
Eosinophils(%) 
 
1.3±0.15 
 
1.44±0.21 
 
1.36±0.23 
 
1.42±0.18 
 
Basophils(%) 
 
0.66±0.51 
 
0.25±0.45 
 
0.25±0.62 
 
0.5±0.52 
 
MCH(pg) 
 
20.95±1.0 
 
20.2±1.96 
 
18.4±3.1 
 
19.10±2.7 
 
MCV(fl) 
 
62.06±2.65 
 
61.39±7.7 
 
60.55±7.22 
 
62.9±6.7 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
Figure:6 
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Figure:7 
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Figure:9 
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Table12 :Effect of Kukil Chooranamon Renal Parameters 
 
Dose(mg/kg) 
 
Control 
 
LD 
 
MD 
 
HD 
 
BUN(mg/dl) 
 
15.91±2.2 
 
15.37±2.7 
 
14.4±3.09 
 
17.14±2.4 
 
Creatinine(mg/dl) 
 
0.86±0.12 
 
0.63±0.18 
 
0.72±0.18 
 
0.72±0.17 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
Figure:12 
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Table :13 Effect of Kukil Chooranamon Hepatic Parameters 
 
Dose(mg/kg) 
 
 
Control 
 
LD 
 
MD 
 
HD 
 
Total Bilirubin(mg/dl) 
 
0.48±0.15 
 
0.34±0.17 
 
0.35±0.16 
 
0.32±0.14 
 
SGOT(U/L) 
 
 
101±14.8 
 
146.25±32.5 
 
131.9±32.1 
 
116.3±40.8 
 
SGPT(U/L) 
 
 
29.8±2.7 
 
36.58±13.1 
 
40.08±15.03 
 
36±10.8 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
Figure:13 
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Figure:14 
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Long term toxicity Study 
Histopathology of Heart  -Control 
 
Plate a. Control                                               Plate b. Low dose group 
 
 
Plate c. Mid dose group                                           Plate d. High dose group 
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Plate a 
 Nucleus appears prominent with regular arrangement of fibres. No evidence of 
pyknotic nucleus. 
 No evidence of collagen deposition in myocardium. 
Plate b 
 Normal network of myocardial fibers were observed 
 No evidence of atherosclerosis and thrombosis 
Plate c 
 Nuclei of cardiomyocytes appears regular size and shape 
 Arrangement of cardiac myofibres was normal 
Plate d 
 Cardiac fibres appears normal with regular striations 
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Long term toxicity Study 
Histopathology of Lungs 
 
 
 
 
 
 
 
 
 
Plate a. Control                                  Plate b. Low dose group 
 
Plate c. Mid dose group   Plate d. High dose group 
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Plate a 
 Lung parenchyma appears normal with regular arrangement of alveoli and 
alveolar sac with no signs of lymphocyte infiltration and pulmonary fibrosis 
 No evidence of lymphocyte aggregation in deep airway layers 
Plate b 
 Normal lung parenchyma with regular airway histology was observed 
 No evidence of perivascular cuffing 
Plate c 
 No evidence of lymphocyte proliferation 
 Appearance of vascular sheath and perivascular regions are normal 
Plate d 
 No signs of airway secretion and bronchial secretion 
 Bronchial blood vessels and connective tissue appears normal with no signs of 
pulmonary oedema 
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Long term toxicity Study 
Histopathology of Liver 
 
 
Plate a. Control          Plate b. Low dose group 
 
 
 
 
 
 
 
 
Plate c. Mid dose group                           Plate d. High dose group 
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Plate a 
 Hepatocytic cytoplasm appears normal. The centrilobular hepatocytes appears 
normal with stained cytoplasm 
 No evidence of mesenchymal reaction on to the hepatic parenchyma. 
Plate b 
 Numerous hepatocytes appears with shrunken nucleus 
 No signs of nodular degeneration and cirrhosis. 
 No evidence of collagen (fibrosis) 
Plate c 
  kupffer cells were Normal 
 No evidence of collagen (fibrosis) 
Plate d 
 Hepatocytic cytoplasm appears normal. The centrilobular hepatocytes appears 
normal with stained cytoplasm 
 No evidence of mesenchymal reaction on to the hepatic parenchyma. 
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Long term toxicity Study 
Histopathology of Stomach 
 
 
 
 
 
 
 
 
Plate a. Control                                    Plate b. Low dose group 
 
 
 
 
 
 
 
 
Plate c. Mid dose group                               Plate  d. High dose group 
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Plate a 
 Mucosal wall appears normal with regular arrangement of connective tissue 
 Histology of gastric wall composed of normal mucosa, muscularismucosa, 
submucosa, muscularispropiria and adventitia 
Plate b 
 Intracytoplasmic zone of mucosa appears normal 
 Histology of gastric wall composed of normal mucosa, muscularismucosa, 
submucosa, muscularispropiria and adventitia. 
Plate c 
 Light microscopic observation stomach reveals normal histology of gastric 
wall composed of normal mucosa, muscularismucosa, submucosa, 
muscularispropiria and adventitia. No signs of ulceration were observed 
Plate d 
 Appearance of glandular lumen was normal. Lamina propria appears normal 
with no evidence of infiltration and inflammation. 
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Long term toxicity Study 
Histopathology of Spleen 
Plate a.Control                                                Plate b. Low dose group 
 
 
 
 
 
 
 
 
Plate c. Mid dose group       Plate d.High dose group  
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Plate a 
 Appearance of red pulp and marginal sinus are normal. No abnormalities 
found in lymph nodes  
Plate b 
 Appearance of marginal sinus was normal 
 Lymphoid follicles appears normal. Marginal sinus (MS) of the rat and its 
sinus lining cells appear normal. Erythropoietic cells (EP) are scattered 
throughout the red pulp. 
Plate c 
 Germinal center, Follicle and Central artery appears normal 
Plate d 
 Mild reduction in cellularity and size of the red pulp 
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Long term toxicity Study 
Histopathology of Kidney 
 
 
 
 
 
 
 
 
 
Plate a. Control                                             Plate b. Low dose group   
 
 
 
 
 
 
 
 
Plate c. Mid dose group                                 Plate d. High dose group 
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Plate a 
 Glomerulus (G) surrounded by a narrow capsular space and the parietal layer 
of Bowman's capsule. 
 Note the proximal convoluted tubules (P) and the distal convoluted tubules 
(D) 
 Epithelial lining on proximal convoluted tubule appears normal 
 Lumen of distal convolutes tubule and collecting duct was normal. 
Plate b 
 Glomerulus (G) surrounded by a narrow capsular space and the parietal layer 
of Bowman's capsule. 
 Note the proximal convoluted tubules (P) and the distal convoluted tubules 
(D) 
 Epithelial lining on proximal convoluted tubule appears normal 
Plate c 
 Glomerulus (G) surrounded by a narrow capsular space and the parietal layer 
of Bowman's capsule. 
 Note the proximal convoluted tubules (P) and the distal convoluted tubules 
(D) 
 Epithelial lining on proximal convoluted tubule appears normal 
Plate d 
 Epithelial lining on proximal convoluted tubule appears normal 
 Lumen of distal convolutes tubule and collecting duct was normal. 
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Long term toxicity Study 
Histopathology of Testis 
 
 
 
 
 
 
 
 
 
Plate a. Control                              Plate b. Low dose group 
 
 
 
 
 
 
 
 
 
Plate c. Mid dose group                              Plate d. High dose group  
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Plate a 
 Presence of mature somatic cells project the perfect histomorphology of 
testicular cells were observed.  
 Primary spermatocytes with large centered nucleus and dense chromatin were 
observed. 
Plate b 
 Normal sertoli cell aligned properly on the basement membrane with oval 
dome shaped nucleus shows the normal morphology of the seminiferous 
tubule were observed. 
Plate c 
 Histo cytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed. 
Plate d 
 Appearance of leydig cells, interstitial tissue, seminiferous tubule, Sertoli cells 
and spermatogonia were normal. 
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Long term toxicity Study 
Histopathology of Uterus 
 
 
 
 
 
 
 
 
Plate a. Control   Plate b. Low dose group 
 
 
 
 
 
 
 
 
 
Plate c. Mid dose group                     Plate d. High dose group 
 
 
 
 
 
 
HISTOPATHOLOGY 
 
 Page 105 
 
Plate a 
 Appearance of endometrium, myometrium and uterine glands was normal.  
 Endometrial gland, epithelium and blood vessels appears normal. 
Plate b 
 Arrangement of uterine layers such Endometrium and myometrium are normal 
with no signs of abnormalities. 
 Arrangement of stratum basale, functionale and surface epithelium seems 
normal 
 Endometrial gland, epithelium and blood vessels appears normal. 
Plate c 
 Arrangement of uterine layers such Endometrium and myometrium are normal 
with no signs of abnormalities. 
 Endometrial gland, epithelium and blood vessels appears normal. 
Plate d 
 Arrangement of uterine layers such Endometrium and myometrium are normal 
with no signs of abnormalities. 
 Arrangement of stratum basale, functionale and surface epithelium seems 
normal. 
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Long term toxicity Study 
Histopathology of Ovary 
 
Plate a. Control                                             Plate b. Low dose group 
Plate c. Mid dose group                  Plate d. High dose group     
 
 
 
 
 
 
HISTOPATHOLOGY 
 
 Page 107 
 
Plate a 
 Histopathological analysis of ovary showing normal corpus luteum (CL) and 
Primordial follicles with few mature ovarian follicles with no signs of 
abnormality.  
Plate b 
 Sequential arrangement of granulosa cells arounds oocyte was normal and 
regular 
 Follicular cells, cytoplasm and nucleus appears normal 
 Appearance of antral follicle, primary oocyte and secondary follicles are 
normal 
Plate c 
 Histopathological analysis of ovary showing normal corpus luteum (CL) and 
Primordial follicles with few mature ovarian follicles with no signs of 
abnormality.  
Plate d 
 Sequential arrangement of granulosa cells arounds oocyte was normal and 
regular 
 Follicular cells, cytoplasm and nucleus appears normal 
Plate e 
 Sequential arrangement of granulosa cells arounds oocyte was normal and 
regular 
 Follicular cells, cytoplasm and nucleus appears normal 
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Long term toxicity Study 
Histopathology of Brain 
 
 
 
 
 
 
 
 
 
Plate a. Control                                              Plate b. High dose  
 
Plate a 
 Regular marginal alignment on the neurons with promising histology .Neurons 
are very intact and there were no signs of oedema or degeneration were 
observed. 
 Section of cerebellum shows distinct molecular and granular layer. Neuronal 
architecture appears normal with sufficient numbers 
 Arrangement of the neurons appears intact with no signs of degeneration or 
apoptotic changes.  
Plate b 
 Cortex region showed normal neurons with polygonal to round cell bodies 
containing dense cytoplasm. 
 Normal appearance of cerebral cortex and medulla with intact parenchyma  
 Neuronal cellular architecture appears normal with regular inter neuronal 
space. 
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OBSERVATION AND RESULTS 
The observation and results were studied and tabulated under the following heading. 
1) Sex distribution 
2) Age distribution 
3) Occupational status 
4) Family History 
5) Diet habits 
6) Thinai reference 
7) Kaalam distribution (According to Age) 
8) Kaalam distribution 
9) Yakkai Ilakkanam (Physical Constitution) 
10) Gunam reference 
11) Duration of illness 
12) Clinical features 
13) Distributions  of three thodams 
14) UdarKattukkal reference 
15) En Vagaithervugal 
16) Neerkkuri reference 
17) Neikkuri reference 
18) VCSS Score (Weekly Assesment) 
19) Result 
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SEX DISTRIBUTION
MALE
FEMALE
17.5%
82.5%
1. Sex distribution: 
 
S.no Sex distribution No of cases Percentage 
1. Male 33 82.5% 
2. Female 7 17.5% 
 
 
 
 
Observation: 
  Among the 40 patients selected for this study, 82.5% were males and 17.5% 
females. 
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2. Age distribution: 
 
S.no Age No of cases Percentage 
1. 20–30 7 17.5% 
2. 31-40 9 22.5% 
3. 41-50 14 35% 
4. 51-60 10 25% 
 
 
 
 
Observation: 
 The patients were selected from all age groups as given above and the 
maximum numbers of patients (14) were in the age between 41 and 50yrs. 
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3. Occupational status: 
Sl. No Nature of Work No. of Cases Percentage 
1 Home Maker 5 12.5% 
2 Farmer 2 5% 
3 Security 4 10% 
4 Businessman 4 10% 
5 Carpenter 1 2.5% 
6 Shop keeper 3 7.5% 
7 Driver 1 2.5% 
8 Administration Work 8 20% 
9 Saloon 3 7.5% 
10 Supervisor 9 22.5% 
 
 
 
Observation: 
 The majority of patients in this study were Administration Work & 
Supervisors. 
CLINICAL OBSERVATION  AND  RESULT 
 
 Page 113 
 
0%
20%
40%
60%
80%
100%
Family history +ve Family history -ve
FAMILY HISTORY
FAMILY HISTORY
100%
4. Family history: 
 
 
 
 
Observation: 
 100% of the patients showed negative family history. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S,no Critaria No of cases Percentages 
1. Family history( + ve) - - 
2.  Family history( - ve) 40 100% 
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5. Dietary habits: 
 
S.no Dietary habits No of cases Percentage 
1. Vegetarian 2 5% 
2. Non-vegetarian 38 95% 
 
 
 
 
 
 
 
 
Observation: 
 95% of the patients were non-vegetarians. 
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6. Thinai reference: 
 
S.no Thinai No of cases Percentage 
1. Kurinji 2 5% 
2. Mullai - - 
3. Marutham 7 17.5% 
4. Neithal 31 77.5% 
5. Paalai - - 
 
 
 
Observation: 
 77.5% of the patients were from Neithal (Coastal Area) and (17.5%) from 
Marutham (Fertile Land) and the remaining (5%) from kurinji (Hill area) 
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7. Kaalam distribution (According to age) 
In Siddha literature human life has been divided into three periods as follows 
1) Vatham 
2) Piththam 
3) Kabam 
The duration of each period is said to be 33 years 
S.no Kaalam No of cases Percentage 
1. Vaatha kaalam(1-33yrs) 11 27.5% 
2. Pitha kaalam(34-66yrs) 29 72.5% 
3. Kaba kaalam(67-100yrs) - - 
 
 
Observation: 
 72.5% of the patients in Pithakaalam and the remaining 27.5%  patients 
reported in Vathakaalam. 
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8. Kaalam distribution: 
 
S.no Kaalam distribution No of cases Percentage 
1. Kaar kaalam - - 
2. Koothir kaalam - - 
3. Mun pani kaalam - - 
4. Pin pani kaalam 30 75% 
5. Ilavenil kaalam 10 25% 
6. Mudhuvenil kaalam - - 
 
 
 
 
 
Observation: 
75% of the patients admitted in Pinpanikaalam and the remaining 25%  patients 
were admitted in Ilavenilkaalam. 
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9. Yaakai ilakkanam(Physical constituents): 
 
S.no Yaakai ilakkanam No of cases Percentage 
1. Vaatha udal - - 
2. Pitha udal - - 
3. Kaba udal - - 
4. Thontha udal 40 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observation: 
 All the patients (100%) had ThonthaUdal. 
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10. Gunam(Quality and Character) 
 
S.no Gunam No of cases Percentage 
1. Sathuva gunam - - 
2. Raso gunam 40 100% 
3. Thamo gunam - - 
 
 
 
Observation: 
 All the patients (100%) had “RasoGunam”. 
 
 
 
 
 
 
CLINICAL OBSERVATION  AND  RESULT 
 
 Page 120 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
DURATION OF ILLNESS
DURATION OF ILLNESS
22.5
7.5%
10%
60%
11. Duration of illness: 
 
S.no Duration of illness No of cases Percentage 
1. 0-3 months 9 22.5% 
2. 4-6months 
 
3 7.5% 
3. 7-9months - - 
4. 10-12months 4 10% 
5. >1yr 24 60% 
 
 
Observation: 
 60% of the patients were suffering with the illness for more than 1 year. 
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12. Clinical features: 
 
S.no Clinical features No of cases Percentage 
1. Ulcer with varicose vein 40 100% 
2. Pain 40 100% 
3. Hyperpigmentation around the ulcer 40 100% 
4. Itching 34 85% 
5. Fibrunous exudate 40 100% 
6. Inflamation 40 100% 
7. Swelling 35 87.5% 
8. Eczema around the ulcer 32 80% 
 
 
 
Observation: 
All patients in the study had clinical features’ of ulcer with varicose vein, oozing, 
pain, hyperpigmentation, inflammation, 85% with itching, 87.5% with swelling and 
80% with eczema around ulcer. 
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13. Distribution of Mukkutram: 
Vaatham: 
 
S.no Vaatham No of cases Percentage 
1. Pranan - - 
2. Abanan 5 12.5% 
3. Uthanan - - 
4. Viyanan 40 100% 
5. Samanan 40 100% 
6. Nagan - - 
7. Koorman - - 
8. Kirugaran - - 
9. Devathathan 2 5% 
10. Dhananjayan - - 
 
 
 
Observation: 
 Samaanan and Viyaanan were affected in all the 40 patients. Abananand 
Devathaththan were affected in 5 and 2 patients respectively 
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Pitham: 
 
S.no Pitham No of cases Percentage 
1. Anar pitham - - 
2. Ranjaga pitham - - 
3. Saathaga pitham 40 100% 
4. Piraasaga pitham 40 100% 
5. Aalosaga pitham - - 
 
 
 
 
 
Observation: 
 Saathaga pitham and Pirasaga pitham were affected in all the cases. 
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Kabam: 
 
S.no Kabam No of cases Percentage 
1. Avalambagam - - 
2. Kilethagam - - 
3. Pothagam - - 
4. Tharpagam - - 
5. Santhikam 1 2.5% 
 
 
 
 
Observation: 
 InKabamsanthikam was affected in 2.5% cases. 
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14. Udar kattugal: 
 
S.no Udar kattugal No of cases Percentage 
1. Saaram 40 100% 
2. Senneer 40 100% 
3. Oon 40 100% 
4. Kozhuppu - - 
5. Enbu - - 
6. Moolai - - 
7. Sukkilam/ Suronitham - - 
 
 
 
 
 
 
Observation: 
 Among 40 patients, Saaram and Seneer were affected in all the cases.  
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15. Envagai thervugal: 
 
Sl. 
No 
Envagai Thervugal No. of Cases Percentage 
1 Naadi 
 
 
a. Vathapiththam 20 50% 
b. Piththavatham 10 25% 
c. Kaba vatham 4 10% 
d. Kaba piththam 6 15% 
2 Sparisam 40 100% 
3 Naa - - 
4 Niram 40 100% 
5 Mozhi - - 
6 Vizhi - - 
7 Malam 5 12.5% 
8 Moothiram - - 
 
In Envagaithervugal, Niram and Sparisam were found affected in all the 40 cases. 
The Naadinadai seen in Naalavibatha pun patients were Vathapitham 50%, 
Pithavatham 25 %,  Kabavatham 10%, Kabapitham15%. 
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16. Neerkuri Reference: 
S.no Neerkuri No of cases Percentage 
1. Pale yellow 20 50% 
2. Yellow 2 5% 
3. Dark yellow 1 2.5% 
4. Straw colour 10 25% 
5. Colourless 7 17.5% 
 
 
 
Observation: 
 In this study 50% of the patients had Neerkkuri with pale yellow, 5% with 
yellow, 2.5% with colourless,25% with dark yellow and 17.5% with straw colour. 
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17. Neikuri Reference: 
 
S.no Neikuri No of cases Percentage 
1. Vaatham(Aravena neendathu) 3 7.5% 
2. Pitham(Aazhi pol paraviyathu) 7 17.5% 
3. Kabam(Muthothu ninrathu) 23 57.5% 
4. Others 7 17.5% 
 
 
 
 
Observation: 
 In this study 7.5% of the patients had Neikuri with Vatham (Aravana 
Neendal),17.5% with Piththam(Azhipol Paraviyathu), 57.5% with 
Kabam(Muththothu ninrathu) and 17.5% with other pattern. 
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18. VCSS SCORE (Weekly assessment) 
OP/IP no 1
st
 day 8
th
 day 15
th
 day 22
nd
 day 29
th
 day 36
th
 day 43
rd
  day 
I 66207 16 13 10 9 7 6 5 
I 60252 23 21 19 18 15 10 5 
H 68569 18 18 17 16 14 13 12 
H 13974 19 17 16 16 15 15 13 
I 67217 13 12 10 9 7 2 1 
IP-9448 17 16 13 10 8 6 2 
I 40853 16 14 12 10 8 6 2 
H 83931 16 15 13 11 8 7 2 
IP-9469 20 18 15 14 12 9 4 
H 61480 20 20 18 17 14 11 5 
F 009361 18 16 16 13 10 6 2 
I 74686 18 16 15 13 11 9 4 
I 69996 12 11 10 10 9 5 2 
IP-8817 21 21 18 17 15 14 9 
IP-9502 23 20 17 15 13 9 5 
I 25352 17 15 12 10 8 4 4 
IP-9507 18 17 15 12 10 7 5 
IP-8824 23 21 19 18 18 17 16 
I8356 18 17 16 14 13 11 11 
I 21367 17 17 16 14 13 12 10 
 
 
 
 
 
 
 
 
CLINICAL OBSERVATION  AND  RESULT 
 
 Page 130 
 
VCSS SCORE (Weekly assessment) 
 
OP/IP no 1
st
 day 8
th
 day 15
th
 day 22
nd
 day 29
th
 day 36
th
 day 43
rd
  day 
H 5501 21 21 18 15 15 14 14 
I 77918 19 17 16 14 12 10 6 
I 78657 18 16 14 12 10 7 2 
G28368 13 13 11 9 7 5 2 
I 33083 20 20 16 15 13 12 11 
I 41069 22 21 18 16 14 12 9 
IP-9540 16 15 14 11 9 6 2 
G 42979 18 17 15 13 10 8 5 
I 78214 14 13 11 9 8 7 3 
IP-8910 18 17 13 11 10 8 4 
I 82898 14 13 13 11 10 5 3 
I 78956 20 18 17 15 13 11 7 
I 88996 18 18 17 15 14 10 7 
IP-9580 20 18 15 11 10 8 4 
I 90263 14 13 13 12 10 8 5 
IP- 9588 19 16 13 10 7 5 2 
I 81527 21 19 17 17 14 11 5 
I 92135 22 20 18 17 16 14 9 
I 16273 17 15 14 13 11 9 4 
I 89809 20 18 17 15 15 9 7 
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OUT COME 
S. No. 
OP/IP 
NO. 
NAME 
AGE / 
SEX 
BT AT VCSS RESULT 
1 I 66207 D.SENTHIL 32/M 16 5 75% Good 
2 I 60252 K.A.SIVAGURU 53/M 23 5 79% Good 
3 H 68569 N.MUNUSAMY 50/M 18 12 39% Mild 
4 H 13974 B.CHENGAMMAL 48/F 19 12 37% Mild 
5 I 67217 C.K.UMESH       36/M 13 1 93.3% Good 
6 IP-9448 P.SEKAR 42/M 17 2 88.3% Good 
7 I 40853 G.SHANTHI 38/F 16 2 87.5% Good 
8 H 83931 M.KANNAN 46/M 16 2 87.5% Good 
9 IP-9469 N.PARANTHAMAN 53/M 20 4 80% Good 
10 H 61480 T.KAMALAKANNAN 50/M 20 5 75% Good 
11 F 009361 N.VINCENT 46/M 18 2 89% Good 
12 I 74686 T.S.MAGESH 39/M 18 4 78% Good 
13 I 69996 P.KAVIMANI 28/M 12 2 84% Good 
14 IP-8817 V.NIRMALA 45/F 21 9 58% Moderate 
15 IP-9502 A.K.PERUMAL 47/M 23 5 79% Good 
16 I 25352 K.THANGARAJ 52/M 17   4 76.5% Good 
17 IP-9507 B.VIJAYAKUMAR 59/M 18 3 83.4% Good 
18 IP-8824 M.BHAVANI 20/F 23 16 30.5% Mild 
19 I8356 S.KRISHNAMOORTHY 21/M 18 11 38.9% Mild 
20 I 21367 P.SURESH 51/M 17 10 42% Mild 
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OUT COME 
S. No. OP NO. NAME 
AGE / 
SEX 
BT AT VCSS RESULT 
21 H 5501 K.CHOKKUSAMY 54/M 21 14 34% Mild 
22 I 77918 C.KAILASH 29/M 19 6 68.5% Moderate 
23 I 78657 N.DURAI RAJ 43/M 18 2 88.9% Good 
24 G28368 N.PALANI 44/M 13 2 85% Good 
25 I 33083 S.JAYAKUMAR 56/M 20 11 45% Mild 
26 I 41069 P.RATHAKRISHNAN 52/M 22 9 59% Moderate 
27 IP-9540 S.SUBASH 44/M 16 2 87.5% Good 
28 G 42979 M.SAKTHIVEL 42/M 18 5 72.5% Moderate 
29 I 78214 K.NARESHKUMAR 32/M 14 3 78.6% Good 
30 IP-8910 R.CHELLAMMAL 56/F 18 4 77.8% Good 
31 I 82898 N.MURALIDHARAN   27/M 14 3 79% Good 
32 I 78956 A.M.GOPI 33/M 20 7 65% Moderate 
33 I 88996 J.PARTHIBAN 26/M 18 7 62% Moderate 
34 IP-9580 K.MURUGESAN 47/M 20 4 80% Good   
35 I 90263 D.GOPALAKRISHNAN 28/M 14 5 64% Moderate 
36 IP- 9588 E.PRAVEEN 33/M 19 2 89.5% Good 
37 I 81527 A.SUDHAKAR 40/M 21 5 76% Good 
38 I 92135 V.NITHYA 40/F 22 9 59% Good 
39 I 16273 A.KUMAR 41/M 17 4 76.5% Good 
40 I 89809 D.DEVI 56/F 20 7 65% Moderate 
 
NOTE:-  
BT : Before Treatment;  AT : After Treatment;  
VCSS SCORE: - 
* VCSS0-25 = 0-25% (Poor) reduction in the VCSS Score in before and after treatment. 
* VCSS25-50 =25-50% (Mild) reduction in the VCSS Score in before and after treatment. 
* VCSS50-75 =50-75% (Moderate) reduction in the VCSS Score in before and after treatment. 
* VCSS 75-100 = 75-100% (Good) reduction in the VCSS Score in before and after treatment. 
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19. RESULTS: 
 The trial drug Kukkil chooranam(Internal) and Thuvara ennai (External) 
were given to 40 patients for 48 days. 
 
 
Observation: 
The trial drug Kukkil chooranam(Internal) and Thuvara ennai (External) were given 
to 40 patients for 48 days.Good improvement was observed in 25 patients (62.5%), 
moderate improvement in 8 patients (20%), and mild improvement in 7 (17.5%) 
cases 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Good Moderate Mild
RESULTS
62.5%
20% 17.5%
Sl. No Results No of Cases Percentage 
1 Good 25 62.5% 
2 Moderate 8 20% 
3 Mild 7 17.5% 
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Mr.S.Subash, 44/M. VCSS SCORE 
Before treatment - 16 
 
 
 
 
After treatment - 2 
 
 
 
 
 
Result- 87.5% improved – Good 
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Mr.B.Vijayakumar, 59/M.  
Before treatment – 18 (VCSS SCORE) 
 
 
 
 
After treatment – 3 (VCSS SCORE) 
 
 
 
 
 
Result – 83.4% improved – Good 
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Mr.K.Nareshkumar, 32/M.  
Before treatment – 14 (VCSS SCORE) 
 
 
 
 
 
 
 
 
 
 
 
 
      After treatment -3(VCSS SCORE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Result -78.6 % improved-- Good 
 
 
 
 
 
  
 
 
LABORATORY 
INVESTIGATIONS 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
 
 
 
            
S. 
No
. 
IP / OP 
NO. 
NAME 
A 
GE 
/ 
SE
X 
Hb (gm/dl) 
TOTAL 
RBC 
COUNT 
(mill/cu.mm) 
ESR 
(mm/hour) 
TOTAL WBC 
(cells/cu.mm) 
BT AT BT AT BT AT BT AT 
1 I 66207 D.SENTHIL 
32/
M 
13.9 12 5 4.9 8 8 7900 7800 
2 I 60252 K.A.SIVAGURU 
53/
M 
14.9 14 5.5 5.2 12 18 9400 7600 
3 H 68569 N.MUNUSAMY 
50/
M 
11.3 10.8 4.2 3.9 32 70 6100 6100 
4 H 13974 B.CHENGAMMAL 
48/
F 
9 8.8 3.7 3.5 132 112 7900 7300 
5 I 67217 C.K.UMESH 
 
36/
M 
16 14.9 5.4 5 12 10 5800 6400 
6 IP-9448 P.SEKAR 
42/
M 
14.3 13.4 5.1 4.6 40 52 8100 8800 
7 I 40853 G.SHANTHI 
38/
F 
12 11.2 5.2 4.7 20 20 8400 7000 
8 H 83931 M.KANNAN 
46/
M 
12.9 13.2 4 3.9 40 30 6400 8300 
9 IP-9469 N.PARANTHAMAN 
53/
M 
11.9 12.2 4.4 4.4 60 90 7800 5000 
10 H 61480 T.KAMALAKANNAN 
50/
M 
13.1 12.5 5.2 4.9 44 80 9700 12500 
11 F 009361 N.VINCENT 
46/
M 
14.5 14 4.7 4.5 12 12 6600 7000 
12 I 74686 T.S.MAGESH 
39/
M 
5.1 15 5 4.9 4 4 6400 6400 
13 I 69996 P.KAVIMANI 
28/
M 
18.4 18 5.5 5.6 8 6 13000 10700 
14 IP-8817 V.NIRMALA 
45/
F 
12.5 12.1 4.5 4.6 12 40 4800 6500 
15 IP-9502 A.K.PERUMAL 
47/
M 
12.9 13.4 4.5 4.6 86 52 8700 8800 
16 I 25352 K.THANGARAJ 
52/
M 
14 14 4.8 4.5 12 12 8000 7900 
17 IP-9507 B.VIJAYAKUMAR 
59/
M 
12 11.9 4.1 4.1 20 42 9300 8800 
18 IP-8824 M.BHAVANI 
20/
F 
8.9 8.9 3.7 4 
Too 
high 
60 7700 7600 
19 I8356 S.KRISHNAMOORTHY 
21/
M 
14.8 14.6 4.9 4.7 12 22 7300 6700 
20 I 21367 P.SURESH 
51/
M 
14.4 14 4.6 4.6 12 14 6300 6300 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
 
S. 
No. 
IP / OP 
No. 
NAME 
AGE 
/ SEX 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
Alkaline 
phosphatase 
BT AT BT BT BT AT 
1 I 66207 D.SENTHIL 32/M 22 20 18 18 65 70 
2 I 60252 K.A.SIVAGURU 53/M 19 19 19 14 73 68 
3 H 68569 N.MUNUSAMY 50/M 14 14 17 15 65 74 
4 H 13974 B.CHENGAMMAL 48/F 11 11 17 31 48 46 
5 I 67217 C.K.UMESH  36/M 18 18 28 23 87 77 
6 IP-9448 P.SEKAR 42/M 11 18.6 20 21.8 70 78 
7 I 40853 G.SHANTHI 38/F 15 17 4 11 78 66 
8 H 83931 M.KANNAN 46/M 10 17 12 18 58 60 
9 IP-9469 N.PARANTHAMAN 53/M 20 18 13 13 69 65 
10 H 61480 T.KAMALAKANNAN 50/M 12 15 14 16 200 152 
11 F 009361 N.VINCENT 46/M 21 30 24 28 50 66 
12 I 74686 T.S.MAGESH 39/M 18 20 29 28 66 70 
13 I 69996 P.KAVIMANI 28/M 29 15 20 13 78 101 
14 IP-8817 V.NIRMALA 45/F 25 13 19 17 63 73 
15 IP-9502 A.K.PERUMAL 47/M 17 16.6 11 11.5 72 71 
16 I 25352 K.THANGARAJ 52/M 13 14 12 13 104 101 
17 IP-9507 B.VIJAYAKUMAR 59/M 13.6 14 18.4 15 59 66 
18 IP-8824 M.BHAVANI 20/F 13.6 20 10 10 79 78 
19 I8356 S.KRISHNAMOORTHY 21/M 22 19 28 24 72 75 
20 I 21367 P.SURESH 51/M 18 20 19 22 67 69 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
          
S.No. OP No. NAME 
AGE 
/ SEX 
SGOT (IU/L) SGPT (IU/L) 
Alkaline 
phosphatase 
BT AT BT AT BT AT 
21 H 5501 K.CHOKKUSAMY 54/M 19 18 14 25 125 143 
22 I 77918 C.KAILASH 29/M 24 20 30 28 60 66 
23 I 78657 N.DURAI RAJ 43/M 15 19 18 21 70 73 
24 G28368 N.PALANI 44/F 14 20 13 12 71 80 
25 I 33083 S.JAYAKUMAR 56/M 18 21 13 15 104 103 
26 I 41069 P.RATHAKRISHNAN 52/M 11 14 16 21 82 82 
27 IP-9540 S.SUBASH 44/M 10 9 18 13 72 65 
28 G 42979 M.SAKTHIVEL 42/M 44 48 60 50 90 96 
29 I 78214 K.NARESHKUMAR 32/M 52 18 6 16 105 101 
30 IP-8910 R.CHELLAMMAL 56/F 14 16 12 20 69 70 
31 I 82898 N.MURALIDHARAN   27/M 18 20 13 25 63 70 
32 I 78956 A.M.GOPI 33/M 40 25 32 37 89 86 
33 I 88996 J.PARTHIBAN 26/M 28 20 61 23 116 98 
34 IP-9580 K.MURUGESAN 47/M 22 17 25 11 70 66 
35 I 90263 D.GOPALAKRISHNAN 28/M 30 28 30 29 60 65 
36 IP- 9588 E.PRAVEEN 33/M 23 9.7 27.6 8.2 89 83 
37 I 81527 A.SUDHAKAR 40/M 13.9 14 11.7 20 81 82 
38 I 92135 V.NITHYA 40/F 18 20 20 25 102 110 
39 I 16273 A.KUMAR 41/M 23 14 29 15 111 85 
40 I 89809 D.DEVI 56/F 20 25 15 20 68 70 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
 
 
        
S. No. 
IP / OP 
NO. 
NAME 
AGE 
/ SEX 
TOTAL 
BILIRUBIN 
DIRECT 
BILIRUBIN 
INDIRECT 
BILIRUBIN 
BT AT BT AT BT AT 
1 I 66207 D.SENTHIL 32/M 0.7 0.8 0.3 0.4 0.4 0.4 
2 I 60252 K.A.SIVAGURU 53/M 0.6 0.4 0.2 0.2 0.4 0.2 
3 H 68569 N.MUNUSAMY 50/M 0.8 0.4 0.4 0.2 0.5 0.2 
4 H 13974 B.CHENGAMMAL 48/F 0.5 0.3 0.2 0.1 0.3 0.2 
5 I 67217 C.K.UMESH  36/M 1 0.8 0.3 0.3 0.7 0.5 
6 IP-9448 P.SEKAR 42/M 0.8 0.5 0.3 0.215 0.5 0.3 
7 I 40853 G.SHANTHI 38/F 0.7 0.6 0.3 0.3 0.4 0.3 
8 H 83931 M.KANNAN 46/M 0.5 0.6 0.3 0.2 0.2 0.4 
9 IP-9469 N.PARANTHAMAN 53/M 0.6 0.5 0.2 0.2 0.4 0.3 
10 H 61480 T.KAMALAKANNAN 50/M 0.2 0.2 0.1 0.1 0.1 0.1 
11 F 009361 N.VINCENT 46/M 2.2 1.8 0.8 0.9 1.4 0.9 
12 I 74686 T.S.MAGESH 39/M 0.7 0.8 0.3 0.4 0.4 0.4 
13 I 69996 P.KAVIMANI 28/M 0.4 0.3 0.2 0.2 0.2 0.1 
14 IP-8817 V.NIRMALA 45/F 0.8 0.7 0.3 0.3 0.5 0.4 
15 IP-9502 A.K.PERUMAL 47/M 0.4 0.44 0.2 0.29 0.2 0.2 
16 I 25352 K.THANGARAJ 52/M 0.4 0.6 0.2 0.3 0.2 0.3 
17 IP-9507 B.VIJAYAKUMAR 59/M 0.29 0.4 0.141 0.3 0.1 0.1 
18 IP-8824 M.BHAVANI 20/F 0.35 0.4 0.179 0.2 0.2 0.2 
19 I8356 S.KRISHNAMOORTHY 21/M 0.5 0.5 0.2 0.3 0.3 0.2 
20 I 21367 P.SURESH 51/M 0.6 0.8 0.3 0.4 0.3 0.4 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
 
 
        
S.NO. OPNO. NAME 
AGE 
/ SEX 
TOTAL 
BILIRUBIN 
DIRECT 
BILIRUBIN 
INDIRECT 
BILIRUBIN 
BT AT BT AT BT AT 
21 H 5501 K.CHOKKUSAMY 54/M 0.6 0.5 0.2 0.3 0.4 0.2 
22 I 77918 C.KAILASH 29/M 0.7 0.7 0.3 0.3 0.4 0.4 
23 I 78657 N.DURAI RAJ 43/M 0.6 0.5 0.2 0.2 0.4 0.3 
24 G28368 N.PALANI 44/F 1.2 0.8 0.5 0.4 0.7 0.4 
25 I 33083 S.JAYAKUMAR 56/M 0.4 0.5 0.2 0.2 0.2 0.3 
26 I 41069 P.RATHAKRISHNAN 52/M 0.7 0.5 0.3 0.2 0.4 0.3 
27 IP-9540 S.SUBASH 44/M 0.5 0.4 0.2 0.2 0.3 0.2 
28 G 42979 M.SAKTHIVEL 42/M 1.6 0.8 0.5 0.4 1.1 0.4 
29 I 78214 K.NARESHKUMAR 32/M 1.6 1.7 0.6 0.7 1 1 
30 IP-8910 R.CHELLAMMAL 56/F 0.4 0.6 0.2 0.3 0.2 0.3 
31 I 82898 N.MURALIDHARAN   27/M 3 1.8 0.6 0.8 2.4 1 
32 I 78956 A.M.GOPI 33/M 1.2 0.9 0.4 0.4 0.8 0.5 
33 I 88996 J.PARTHIBAN 26/M 0.7 0.7 0.3 0.3 0.4 0.4 
34 IP-9580 K.MURUGESAN 47/M 0.7 0.6 0.2 0.3 0.4 0.3 
35 I 90263 D.GOPALAKRISHNAN 28/M 0.9 0.9 0.3 0.4 0.6 0.5 
36 IP- 9588 E.PRAVEEN 33/M 1.56 0.62 0.67 0.31 0.83 0.3 
37 I 81527 A.SUDHAKAR 40/M 0.59 0.6 0.25 0.3 0.3 0.3 
38 I 92135 V.NITHYA 40/F 0.5 0.7 0.2 0.3 0.3 0.4 
39 I 16273 A.KUMAR 41/M 1.4 1.5 0.5 0.6 0.9 0.9 
40 I 89809 D.DEVI 56/F 0.6 0.8 0.3 0.5 0.3 0.3 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
S. 
No
. 
IP / OP 
No. 
NAME 
AGE
/ 
SEX 
BLOOD (mg/dl) 
UREA  
CREATINI
NE (mg/dl) 
FASTING 
(mg/dl) 
POST 
PRANDIAL 
(mg/dl) 
BT AT BT AT BT AT BT AT 
1 I 66207 D.SENTHIL 32/M 100 105 124 120 19 18 1 1 
2 I 60252 K.A.SIVAGURU 53/M 94 97 128 96 23 27 1.1 1.2 
3 H 68569 N.MUNUSAMY 50/M 100 96 116 116 24 28 1.1 1 
4 H 13974 B.CHENGAMMAL 48/F 102 108 120 110 26 35.9 0.9 1.2 
5 I 67217 C.K.UMESH 
 
36/M 
106 100 93 76 26 21 1.3 1.2 
6 IP-9448 P.SEKAR 42/M 99 93 126 129 12 20.6 0.9 1.8 
7 I 40853 G.SHANTHI 38/F 100 85 118 112 11 17 0.9 0.8 
8 H 83931 M.KANNAN 46/M 103 93 115 109 13 16 1 1.1 
9 IP-9469 N.PARANTHAMAN 53/M 93 89 115 102 18 18 1 1.1 
10 H 61480 T.KAMALAKANNAN 50/M 115 113 116 158 15 14 1 1 
11 F 009361 N.VINCENT 46/M 102 102 92 112 15 15 1 1.1 
12 I 74686 T.S.MAGESH 39/M 113 110 105 120 19 20 1 1 
13 I 69996 P.KAVIMANI 28/M 100 88 82 90 17 14 1.1 1 
14 IP-8817 V.NIRMALA 45/F 92 110 109 118 17 22 0.7 0.9 
15 IP-9502 A.K.PERUMAL 47/M 111 85.3 117 116 29 37.8 1 0.96 
16 I 25352 K.THANGARAJ 52/M 103 110 114 120 37 35 1.7 1.1 
17 IP-9507 B.VIJAYAKUMAR 59/M 97 107 119 123 17.9 14 0.88 0.9 
18 IP-8824 M.BHAVANI 20/F 98 99 109 111 14.4 20 0.94 1 
19 I8356 S.KRISHNAMOORTHY 21/M 102 94 119 98 24 11 1 1.1 
20 I 21367 P.SURESH 51/M 111 110 114 112 19 20 1 1 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
 
           
S.
No
. 
OPNo. NAME 
AG
E / 
SE
X 
BLOOD (mg/dl) 
UREA  
CREATINI
NE (mg/dl) FASTING 
(mg/dl) 
POST 
PRANDIAL 
(mg/dl) 
BT AT BT AT BT AT BT AT 
21 H 5501 K.CHOKKUSAMY 
54/
M 
114 123 126 126 18 21 1 1 
22 I 77918 C.KAILASH 
29/
M 
97 90 122 130 15 14 0.9 1 
23 I 78657 N.DURAI RAJ 
43/
M 
106 92 112 110 26 20 1.1 1 
24 G28368 N.PALANI 
44/
F 
98 100 126 117 13 12 1.1 1 
25 I 33083 S.JAYAKUMAR 
56/
M 
88 98 113 110 21 23 1.2 1.2 
26 I 41069 P.RATHAKRISHNAN 
52/
M 
107 115 134 117 13 16 1 0.9 
27 IP-9540 S.SUBASH 
44/
M 
108 107 119 108 19 14 1 1 
28 G 42979 M.SAKTHIVEL 
42/
M 
82 91 103 110 17 13 0.9 0.9 
29 I 78214 K.NARESHKUMAR 
32/
M 
100 107 116 116 13 13 1 1 
30 IP-8910 R.CHELLAMMAL 
56/
F 
104 105 138 112 22 40 1.1 1 
31 I 82898 N.MURALIDHARAN 
  
27/
M 
83 90 72 100 16 20 1.3 1.2 
32 I 78956 A.M.GOPI 
33/
M 
108 107 120 112 30 17 1 0.9 
33 I 88996 J.PARTHIBAN 
26/
M 
92 91 113 116 39 26 1 0.9 
34 IP-9580 K.MURUGESAN 
47/
M 
94 82 144 112 18 17 1.3 0.8 
35 I 90263 D.GOPALAKRISHNAN 
28/
M 
99 100 130 121 22 22 1.3 1.2 
36 IP- 9588 E.PRAVEEN 
33/
M 
113.5 110 133 113.3 19.8 24.3 1.26 0.99 
37 I 81527 A.SUDHAKAR 
40/
M 
110 108 147 120 39.4 40 1.01 1 
38 I 92135 V.NITHYA 
40/
F 
98 90 110 110 23 20 4.5 5.2 
39 I 16273 A.KUMAR 
41/
M 
108 105 121 120 28 21 1 0.8 
40 I 89809 D.DEVI 
56/
F 
108 107 115 120 25 26 1.1 1 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
              
S. 
No
. 
IP / OP 
No. 
NAME 
A
G
E / 
SE
X 
URINE   
SUGAR 
(F) 
URINE 
SUGAR 
(PP) 
ALBUMI
N 
DEPOSITS 
Epithelial 
cells 
Pus cells 
BT AT BT AT BT AT BT AT BT AT 
1 I 66207 D.SENTHIL 
32/
M 
NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
2 I 60252 K.A.SIVAGURU 
53/
M 
NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 2-4 
3 
H 
68569 
N.MUNUSAMY 
50/
M 
NIL NIL NIL NIL NIL NIL 2-3 1-2 2-3 2-4 
4 
H 
13974 
B.CHENGAMMAL 
48/
F 
NIL NIL NIL NIL NIL NIL 1-2 1-2 2-4 1-2 
5 I 67217 C.K.UMESH 
 
36/
M 
NIL NIL NIL NIL NIL NIL 2-3 1-2 6-7 1-2 
6 IP-9448 P.SEKAR 
42/
M 
NIL NIL NIL NIL NIL NIL 2-3 2-4 6-7 2-4 
7 I 40853 G.SHANTHI 
38/
F 
NIL NIL NIL NIL NIL NIL 2-4 1-2 2-4 1-2 
8 
H 
83931 
M.KANNAN 
46/
M 
NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 2-3 
9 IP-9469 N.PARANTHAMAN 
53/
M 
NIL NIL NIL NIL NIL NIL 1-2 1-2 2-4 2-3 
10 
H 
61480 
T.KAMALAKANNAN 
50/
M 
NIL NIL NIL NIL NIL NIL 4-5 1-2 1-2 2-3 
11 
F 
009361 
N.VINCENT 
46/
M 
NIL NIL NIL NIL NIL NIL 1-2 2-4 1-2 1-2 
12 I 74686 T.S.MAGESH 
39/
M 
NIL NIL NIL NIL NIL NIL 1-2 2-4 3-5 3-5 
13 I 69996 P.KAVIMANI 
28/
M 
NIL NIL NIL NIL NIL NIL 1-2 3-5 1-2 1-2 
14 IP-8817 V.NIRMALA 
45/
F 
NIL NIL NIL NIL NIL NIL 1-2 2-4 3-5 2-4 
15 IP-9502 A.K.PERUMAL 
47/
M 
NIL NIL NIL NIL NIL NIL 2-4 2-4 2-4 2-4 
16 I 25352 K.THANGARAJ 
52/
M 
NIL NIL NIL NIL NIL NIL 2-3 2-4 2-3 2-4 
17 IP-9507 B.VIJAYAKUMAR 
59/
M 
NIL NIL NIL NIL NIL NIL 1-2 2-3 1-2 1-2 
18 IP-8824 M.BHAVANI 
20/
F 
NIL NIL NIL NIL NIL NIL 6-8 6-8 8-10 8-10 
19 I8356 S.KRISHNAMOORTHY 
21/
M 
NIL NIL NIL NIL NIL NIL 2-3 1-2 2-3 1-2 
20 I 21367 P.SURESH 
51/
M 
NIL NIL NIL NIL NIL NIL 1-2 1-2 2-4 1-2 
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INVESTIGATIONS BEFORE AND AFTER TREATMENT 
              
S. 
N
o. 
IP / OP 
No. 
NAME 
A
G
E / 
S
E
X 
URINE   
SUGAR (F) 
URINE 
SUGAR 
(PP) 
ALBUMIN 
DEPOSITS 
Epithelial 
cells 
Pus cells 
BT AT BT AT BT AT BT AT BT AT 
21 H 5501 K.CHOKKUSAMY 
54
/M 
NIL NIL NIL NIL NIL NIL 3-5 1-2 2-4 2-4 
22 I 77918 C.KAILASH 
29
/M 
NIL NIL NIL NIL NIL NIL 2-4 2-4 2-4 2-4 
23 I 78657 N.DURAI RAJ 
43
/M 
NIL NIL NIL NIL NIL NIL 2-4 1-3 4-5 2-4 
24 G28368 N.PALANI 
44
/F 
NIL NIL NIL NIL NIL NIL 2-4 1-2 2-4 1-2 
25 I 33083 S.JAYAKUMAR 
56
/M 
NIL NIL NIL NIL NIL NIL 4-5 1-2 1-2 1-2 
26 I 41069 P.RATHAKRISHNAN 
52
/M 
NIL NIL NIL NIL NIL NIL 1-2 2-4 1-2 2-4 
27 IP-9540 S.SUBASH 
44
/M 
NIL NIL NIL NIL NIL NIL 1-2 2-4 1-2 4-6 
28 G 42979 M.SAKTHIVEL 
42
/M 
NIL NIL NIL NIL NIL NIL 1-2 1-2 2-4 3-5 
29 I 78214 K.NARESHKUMAR 
32
/M 
NIL NIL NIL NIL NIL NIL 1-2 2-4 1-2 2-4 
30 IP-8910 R.CHELLAMMAL 
56
/F 
NIL NIL NIL NIL NIL NIL 3-5 3-5 3-5 2-4 
31 I 82898 N.MURALIDHARAN 
  
27
/M 
NIL NIL NIL NIL NIL NIL 2-4 2-4 4-5 2-4 
32 I 78956 A.M.GOPI 
33
/M 
NIL NIL NIL NIL NIL NIL 4-5 2-4 1-2 2-4 
33 I 88996 J.PARTHIBAN 
26
/M 
NIL NIL NIL NIL NIL NIL 2-4 6-7 6-7 
Loa
ded 
34 IP-9580 K.MURUGESAN 
47
/M 
NIL NIL NIL NIL NIL NIL 1-2 1-2 2-3 1-2 
35 I 90263 D.GOPALAKRISHNAN 
28
/M 
NIL NIL NIL NIL NIL NIL 1-2 1-2 2-4 2-4 
36 IP- 9588 E.PRAVEEN 
33
/M 
NIL NIL NIL NIL NIL NIL 2-4 2-4 2-4 2-4 
37 I 81527 A.SUDHAKAR 
40
/M 
NIL NIL NIL NIL NIL NIL 2-4 2-4 2-4 1-2 
38 I 92135 V.NITHYA 
40
/F 
NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
39 I 16273 A.KUMAR 
41
/M 
NIL NIL NIL NIL NIL NIL 6-8 1-2 plenty 8-10 
40 I 89809 D.DEVI 
56
/F 
NIL NIL NIL NIL NIL NIL 1-2 1-2 3-5 2-4 
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STATISTICAL ANALYSIS 
 
All collected data were entered into MS Excel software using different 
columns as variables and rows as patients. SPSS software was used to perform 
statistical analysis. Basic descriptive statistics include frequency distributions and 
cross-tabulations were performed. The quantity variables were expressed as Mean ± 
Standard Deviation and qualitative data as percentage. A probability value of <0.05 
was considered to indicate as statistical significance. Paired‘t’ test was performed for 
determining the significance between before and after treatment.  
 
Paired Sample Statistics (VCSS Score Before Treatment and After Treatment) 
 
Variable Obs Mean±SD t Value p Value 
Before treatment 40 18.17±2.8 
t=24.38 p <0.0001) 
After treatment 40 5.67±3.77 
 
The mean± standard deviation of VCSS score at before and after treatment 
were 18.17±2.8 and 5.67±3.77 respectively which is statistically extremely significant 
(t=24.38, p=0.0001).  
Reduction of VCSS Score before and after treatment 
VCSS score No of patients Before    
         treatment 
After treatment 
<10 0 33 
10-15 6 7 
16-20 26 0 
21-25 8 0 
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DISCUSSION 
 The varicose ulcer (VU) is one of the most severe manifestations of chronic 
venous insufficiency (CVI) of the lower limbs, a disease of great importance to public 
health due to its high incidence and prevalence and because of the high 
socioeconomic impact that it brings, since it is difficult to treat and requires prolonged 
work absenteeism.  
 The trial drugs were prepared in Gunapadam lab of National Institute of 
Siddha after the authentication of the raw drugs by Assistant professor of medicinal 
botany NIS and CCRS Arumbakkam, Chennai.The trail drug was prepared by 
standard operating procedure as mentioned in the Protocol. 
 The Bio chemical analysis was done at the biochemistry lab of NIS and the 
results were documented. The Bio-chemical analysis of Kukkil chooranam had 
shown the presence of Chloride, Phosphate, Carbonate, Calcium, Potassium, 
Nitrite, Iron, Tannic acid, starch and Alkaloids. 
In Short term carried out as per WHO guideline, there was no treatment-
related death or signs of toxicity developed in albino rats at dosage levels of 
2000mg/kg body weight through out the study period. Further, no gross pathological 
changes have been seen in the internal organs of both control and treated groups. 
Thus, the LD50 value was found to be greater than 2000mg/kg body weight, and this 
provides direct relevance for protecting human and animal health. 
To ensure the safety of Kukkil Chooranam, Long term Toxicity Study was 
also carried out as per WHO guideline. Except for hyperactivity at the time of drug 
administration, no other signs of toxicity were noted. After blood collection, all the 
animals were euthanized for gross pathological examinations of all major internal 
organs. The blood samples were sent to a lab for hematological and biochemical 
analysis.  The organs were weighed and preserved in 10% buffered formalin solution 
before sending for histopathological study. All there ports were statistically analyzed. 
 Kukkil Chooranam no Significant in Food intake the test group animals were 
observed when compared with control group during the study 
period(Table7,8,&Figure2,3) The hemopoietic system serves as an important target 
for toxic chemicals and is a sensitive index for pathological conditions both in humans 
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and animals.In Haematological parameters, it had been observed normal in high dose 
level (Table11&Figure 6, 7, 8, 9, 10, 11). Transaminases (SGOT and SGPT) are good 
indicators of liver function and biomarkers to predict the possible toxicity of drugs. 
Any elevation pertaining to these enzymes indicate their out flow into the blood 
stream due to damage in liver parenchymal cells, there was normal limits in SGOT 
and SGPT (Table–13&Figure 13, 14) in high dose treated animals, when compared to 
control group.  In the present study, there was no treatment-related abnormality in 
renal functions at all the animals (Table -12&Figure-12). The therapeutic dose of 
Kukkil Chooranam is 2gMS/day for the human uses mentioned in Siddha text. This 
dose was safest dose in humans for the above studies.  
The histopathological study, organs such as brain, heart, kidney, liver, lungs, 
spleen and stomach were taken. In organs of Control group, no abnormality was 
detected during the study period. 
 The Literature Review reveals that there was no such research has been done 
on Kukkil Chooranam. As an initial step, in this present study, a part of 
standardization of this drug and its safety has been confirmed through necessary 
analysis and Short term & Long term Toxicity studies as per WHO guidelines. 
 The clinical study was conducted with a well-defined protocol and a proper 
proforma after the approval of Institutional Ethical Committee. 
 For this dissertation study, 40 patients were selected and Patients were 
treated in the OP/IP department of SirappuMaruthuvam, in Ayothidoss Pandithar 
Hospital - National Institute of Siddha, Tambaram Sanatorium, Chennai –600 047. 
 Based on various criteria, the data were collected and tabulated. The criteria 
were family history, sex predominance, age distribution, occupation, dietary habits 
and incidence of the disease with reference to thinai, seasonal variation, clinical 
manifestations and assessment of the improvement in the prognosis of the disease 
with the trial drug. 
 In Siddha System, it is necessary to bring the vitiated humours to 
equilibrium. Hence before the treatment Agathiyar kuzhambu with sangankuppi 
(Clerodenruminerme) juice was given for Viresanam (Purgation) in the early 
morning to normalize the vitiated humours.During the treatment, the patients were 
advised to follow pathiyam (Dietary regimen). 
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Internal Drug  : Kukkil chooranam- 1gm two times per day with honey. 
External Drug : Thuvara ennai for external application. 
 Duration of Drug : 48 days 
 40 patients of both genders were recruited for this study. Among the 40 
patients, 33 (82.5%) patients were males and 7(17.5%) patients were females. 
Generally Naalavibathapun Occurs with almost equal frequency in males and 
females, evidencing the losses that this disease causes in work production. But a 
slightly higher prevalence noticed in males. In this study, more number of Male 
cases were reported. 
 Among 40 patients, 7 (17.5%) patients between 20 and 30 years, 9 (22.5%) 
patients between 31 and 40 years, 14 (35%) patients between 41 and 50 years, 10 
(25%) patients between 51 and 60 years. Naalavibatha puncommonly appear at old 
age than younger. In this present study, considerable numbers of patients were 
reported (14 patients) between the age of 41-50 among study sample. 
 The majority of patients in this study were Supervisors 9 (22.5%), 
Administration Work 8 (20%) and Home Maker 5 (12.5%). 
 The majority of patients in this study were Non vegetarian 38 (95%) 
remaining 2 (5%) patients were vegetarian.  
 In this present study, considerable numbers of patients were reported from 
Neithal(31 patients),Marutham(7 patients)Kurinji (2 patients)thinai. 
          Highest number of patients 30(75%) were admitted during PinpaniKaalam 
(Maasi&Panguni) and 10 patients (25%) were admitted during IllavenilKaalam 
(Chithirai & Vaigasi).   
 Most of patients 24 (60%) were affected in durations of above 1 year, 4 
(10%) patients were affected by the illness from 10 to 12 months, 3 (7.5%) patients 
were affected by the illness from 4 to 6 months and 9 (22.5%) patients were affected 
by the illness from 0 to 3 months. 
 Out of 40 (100%) patients 40 patients had clinical features of Ulcer, Pain, 
Hyperpigmentation, Fibrinous exudate and Inflammation, 34 (85%) patients had 
itching, 35 (87.5%) patients had leg swelling, 32 (80%) patients had eczema around 
the ulcer.  
 Laboratory investigations were done for all the cases before and after 
treatment. There were no variations in hepatic, renal and other parameters.  
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 The outcome of this study was clinically observed by VCSS Score, which 
showed encouraging results of good improvement in 25 patients (62.5%), moderate 
improvement in 8 patients (20%), and mild improvement in 7 Patients(17.5%).  
 In this study, no adverse events were observed during the course of the 
treatment. At the time of discharge, all the patients were advised to attend Out-
Patient Department of Sirappu Maruthuvam of NIS for further follow-up treatment. 
 
 
 
  
 
 
SUMMARY 
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SUMMARY 
 The disease Naalavibatha pun was taken for the clinical study with 
KukkilChooranam as internal medicine and Thuvaraennai as external application. 
For the clinical study, 40 cases were selected based on the approved protocol. 
 This study has been approved by IEC of NIS[Date of IEC Approval& its 
number: NIS/IEC/9-2014-15/14-26.08.2015]. Animal studies were carried out after 
obtaining approval from the Institutional Animal Ethical Committee (IAEC) and the 
trial was registered in Clinical Trial Registry of India (CTRI/2017/05/008584). 
Hence the study is safely executed on patients and there was no adverse drug 
reactions noted during the study period. 
 The toxicological evaluations were conducted as per WHO guidelines for 
safety evaluation of Kukkil Chooranam. In long term toxicity study, no signs of 
toxicity and mortality were observed throughout the study period up to the dose of 
2000mg/kg body weight. Thus, the LD50 value of Kukkil Chooranam was found to 
be greater than 2000mg/kg body weight. 
In Long term toxicity study, there were no significant changes in behavioral 
signs, food intake, water intake, Lipid Profile, Renal parameters hematological 
parameters, and Hepatic parameters. The liver function test conducted at the end of 
the study, test groups (Low, Mid, High dose) revealed no significant changes in level 
of liver parameters, when compared with control group animals.  
In organs of Control group, no abnormality was detected. The normal 
histological structure present in test group of animals.     
 Out of the 40 cases, 10 cases were treated in IPD and remaining 30 cases 
were treated in OPD of Ayothidoss Pandithar Hospital of National Institute of 
Siddha, Chennai-47. The detailed study on Naalavibatha pun with reference to its 
aetiology, pathogenesis, investigations, clinical features, diagnosis and treatment 
with trial drugs were done.  
 The results were observed by VCSS score. Among the 40 cases treated, 
62.5% cases had shown Good improvement, 20% cases had shown Moderate 
improvement and 17.5% had shown Mild improvement.  
 
  
 
 
CONCLUSION 
CONCLUSION 
 
 Page 152 
 
CONCLUSION 
 
The present clinical study confirms the efficacy of the trial drugs Kukkil 
chooranam(Internally) and Thuvara Ennai(Externally). It was found to be good 
resulting on Naalavibatha pun patients in reducing clinical symptoms like ulcer, 
itching, oozing, pain and oedema.   
The Short term and Long term toxicitystudiesdid not show any toxic effects in 
the animal. 
 The quantitative outcome of VCSS score shows there is significant reduction 
between before and after treatment. The qualitative outcome shows there is 62.5% of 
cases had shown good improvement, 20% of cases had shown moderate improvement 
and remaining 17.5% of cases had shown mild improvement. 
 The clinical trial conducted in selected patients was satisfactory and the 
results were encouraging. However a study with large number of patients is required 
to fine out the ideal dose response. 
 The cost of the trail medicines are Low. These drugs are easily available and 
the dosage is also convenient. 
 These drugs may be taken up for further exploratory randomised clinical 
trials to confirm the efficacy.   
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ANNEXURE 
The following certificate are enclosed 
 Research Methodology Certificate 
 IEC Certificate 
 IAEC Certificate 
 Authentication Certificate 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST -  GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
Preclinical and clinical study of siddha drug “kukkil chooranam” (internal) and 
“thuvara ennai” (external) in the treatment of   pun (naalavibatha viranam-varicose 
ulcer).  
FORM l - SCREENING & SELECTION PROFORMA  
SL.NO                                     OP NO:   
NAME:    AGE/GENDER:                CONTACT NO: 
INCLUSION CRITERIA 
Age :20-60Yrs                                                                                               Yes/ No Fibrunous exudate
 
Yes/ No 
Sex M/F Skin pigmentation 
 
Yes/ No 
 Ulcer with varicose 
vein 
Yes/ No Inflammation 
 
Yes/ No 
Pain Yes/ No Induration                                                                                                             
 
Yes/No 
Edema 
 
Yes/ No Itching 
 
Yes/No 
Eczema around ulcer 
 
Yes/ No Permit to take photograph Yes/ No 
Willing to give 
blood for 
investigation 
Yes/ No Willing to participate in trial 
and signing consent by 
fulfilling the condition of   
Performa. 
Yes/ No 
If the symptom more than 3, may be included for the clinical trial. 
EXCLUSION CRITERIA: H/O 
Diabetes mellitus Yes/No Gangrene 
 
Yes/ No 
Tuberculous ulcer Yes/No Hanson’s disease Yes/No 
Diabetic ulcer Yes/No Any other systemic 
illness 
Yes/No 
 
ADMITED TO TRIAL:YES   NOIf yes, serial No: 
  OPD    IPD 
Date:        
Station:  Signature of the Lecturer:                                               
Signature of the Investigator:   Signature of the HOD  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST -  GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “KUKKIL CHOORANAM” 
(INTERNAL) AND “THUVARA ENNAI” (EXTERNAL) IN THE TREATMENT OF   PUN 
(NAALAVIBATHA PUN-VARICOSE ULCER). 
 [PRINCIPAL INVESTIGATOR] 
FORM II – HISTORY TAKING FORM 
STUDY NO                                                                         OP / IP NO:    
NAME:                                                                                 AGE/GENDER:  
ADDRESS:                                                                           CONTACT NO: 
                                                                                                  RELIGION:  H / M / C / O          
OCCUPATION:                                                                     INCOME: 
MARRITAL STATUS:    MARRIED                                 UNMARRIED         
DATE OF INITIAL ASSESSMENT:                                       
COMPLAINTS & DURATION: 
 
PERSONAL HISTORY: 
 
         PERSONAL HABITS YES NO IF YES SPECIFY 
DURATION 
AMOUNT/Qty 
             Smoking     
 Tobacco Chewing     
            Alcohol     
Narcotic  Drug  
Addiction 
    
 
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
 FAMILY HISTORY: 
 Whether this problem runs in family?         1. Yes                              2.No         
 If yes, mention the relationship of affected person(s) 
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1._________________     2._________________ 
DIETARY HABIT:   1.Vegetarian                                              2.Non-vegetarian 
 MENSTURAL HISTORY AND OBSTETRIC HISTORY: 
FORM II a 
GENERAL EXAMINATION: 
1. Body weight [Kg]    :                      
2. Height [cms] :                        
3. Body Temperature [0F]       :   
4. Blood Pressure (mm/Hg)  :      
5. Pulse Rate /min. : 
6. Heart Rate / min.  : 
7. Respiratory Rate /min.  :   
Yes            No   
8. Pallor  :   
9. Jaundice  :   
10. Clubbing  : 
11. Cyanosis  : 
12. Pedal Oedema  : 
13. Lymphadenopathy           :  
14. Jugular venous pulsation  :   
 
 VITAL ORGANS EXAMINATION:         Normal          Abnormal 
1.  Heart 
2. Lungs  
3. Brain 
4. Liver 
5. Kidney 
6. Spleen 
7. Stomach   
 
SYSTEMIC EXAMINATION:Normal          Abnormal 
1. Cardio-vascular system 
2. Respiratory system         
3. Gastro intestinal system 
4. Central nervous system 
5.  Uro-genital system     
6.  Endocrine system        
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SIDDHA SYSTEM OF EXAMINATION  
1. THEGI (TYPE OF BODY CONSTITUTION): 
1. Vaatha udal                                          3. Kaba udal                   
2. Pitha udal                                          4. Thontha udal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji                                            3. Paalai 
2. Mullai                                             4. Neithal 
5. Marutham 
3. KAALAM: 
1. Kaar kaalam                                          4. Pinpani kaalam 
2. Koothir kaalam                                       5. Ilavenil kaalam 
3. Munpani kaalam                                     6. Muthuvenil kaalam 
4. GUNAM: 
1. Sathuvam                                                 2. Rasogunam 
3. Thamogunam 
5. PORIPULANGAL (SENSORY ORGANS):          
 
6.KANMENDRIYAM (MOTOR ORGANS) : 
7. KOSANGAL (SHEATH):          
 Before treatment After treatment 
Mei (Skin) Normal  / Affected Normal  / Affected 
Vai (Tongue) Normal  / Affected Normal  / Affected 
Kann (Eye) Normal  / Affected Normal  / Affected 
Mooku (Nose) Normal  / Affected Normal  / Affected 
Sevi (Ear) Normal  / Affected Normal  / Affected 
 Before treatment After treatment 
Kai  Normal  /Affected Normal  /Affected 
Kaal Normal  /Affected Normal  /Affected 
Vai Normal  /Affected Normal  /Affected 
Eruvai Normal  /Affected Normal  /Affected 
Karuvai Normal  /Affected Normal  /Affected 
 Before treatment After treatment 
Annamayakosam Normal  /Affected Normal  /Affected 
Pranamayakosam Normal  /Affected Normal  /Affected 
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8.SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 Before treatment After treatment 
Saaram Normal  /Affected Normal  /Affected 
Senneer Normal  /Affected Normal  /Affected 
Oon Normal  /Affected Normal  /Affected 
Kozhuppu Normal  /Affected Normal  /Affected 
Enbu Normal  /Affected Normal  /Affected 
Moolai Normal  /Affected Normal  /Affected 
Sukkilam / Suronitham Normal  /Affected Normal  /Affected 
 
8.UYIR THATHUKKAL (THREE HUMOURS): 
A. VALI 
 1
st
 day 8
th
day 15
th
 day 22
nd
 day 29
th
day 36
th 
day 43
rd
  day 49
th
 day 
Praanan Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Abaanan Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Viyaanan Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Udhaanan Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Samaanan Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Naagan Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Koorman Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Kirukaran Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Devathathan Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Dhananjeyan Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Manomayakosam Normal  /Affected Normal  /Affected 
Vignanamayakosam Normal  /Affected Normal  /Affected 
Ananthamayakosam Normal  /Affected Normal  /Affected 
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B) AZHAL 
 1
st
day 8
th
 Day
 
15
th
 day 22
nd
 day 29
th
 day 36
th
 day 
 
43
rd
day 
 
49
th
  day 
Analakam 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Prasakam  
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Ranjakam 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Aalosakam 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Saathakam 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
 
C. IYAM:             
 1st  day 8th day 15thday 22nd day 29thday 36thday 43rdday 49th day 
Avalambag
am 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Kilethagam Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Pothagam Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Tharpagam
  
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Santhigam
  
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
 
 
9.SEVEN UDAL DHATHUS: (7 SOMATIC COMPONENTS)  
 1st day 8thday 15thday 22nd day 29thday 36th day 43rdday 49th day 
Saaram Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Senneer  Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Oon Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Kozhuppu Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Enbu Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
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Moolai Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Sukkilam 
/ 
Suronitha
m  
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
Normal  
/Affected 
 
ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION]  
I. NAADI: [PULSE PERCEPTION] 
II. SPARISAM: 
1st Day 8
th
 Day 15
th
 Day 22
nd 
day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
        
 
III. NAA:[TONGUE] 
1st Day 8
th
 Day 15
th
 Day 22
nd 
Day 29
th
 Day 36
th 
Day 43
rd
 Day 49
th
 Day 
        
 
VI.NIRAM: [COMPLEXION]   
     1. Vaatham                                              3. Kabam 
     2. Pitham 
 
V.MOZHI: [VOICE] 
1. High Pitched                                     2. Low Pitched 
3. Medium Pitched 
 
VI.VIZHI: [EYES]  
1st Day 8
th
 Day 15
th
 Day 22
nd 
Day 29
th
 Day 36
th 
Day 43
rd
 Day 49
th
 Day 
        
 
 
1
st
Day 8
th 
day
 
15
th
day 22
nd
day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
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VII. MALAM: [BOWEL HABITS / STOOLS] 
     Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
 
 VIII. MOOTHIRAM [URINE EXAMINATION]   
Neerkkuri Before treatment After treatment 
Niram 
 
  
Manam   
Edai   
Nurai   
Enjal   
 
NEIKURI Before treatment After  treatment 
Aravu (Serpentine fashion)   
Aazhi (Annular/Ringed fashion)   
Muthu (Pearl beaded fashion)   
Kalappu (Mixed fashion)   
Other fashion   
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CLINICAL EXAMINATION:                  
CLINICAL EXAMINATION OF WOUND: 
1.Site:     ------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
-------------------- 
2.Duration:------------------------------ 
3. Size:  
 1
st
 Day 8
th
 Day 15
th
 
Day 
22
th
 
Day 
29
th
 
Day 
36
th
 
Day 
43
rd
 
Day 
49
th
 
Day 
Length         
Width         
Depth         
 
4. Shape:               Irregular    Oval   Semi lunar 
5. Nature of  Edges: Undetermined  Sloping edges        Everted  
Punched out          Raised  
6.Character of the Floor:     Pale granulation tissue              Black mass  
       Red granulation tissue  Wash leather slough 
7.Discharge:                                  Present                            Absent 
8.Associated pain: Present  Absent 
9.Surrounding skin:            Hyperpigmented   Hypopigmented                 
Erythematous 
10. Lymph node enlargement:      Present             Absent 
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FORM II B-CLINICAL ASSESSMENT DURING AND AFTER TRIAL 
OP/ IP NO:                               STUDY NO: NAME: 
AGE/GENDER:              DATE OF RECRUITMENT: 
VENOUS CLINICAL SEVERITY SCORE 
ATTRIBUTE ABSENT=0        MILD=1        MODERATE=2          SEVERE=3 
 
 
PAIN 
 
None 
 
Occasional, 
not 
Restricting 
activity or 
requiring pain 
Medication 
 
Daily moderate activity 
imitation; occasional 
Pain medication 
 
Daily, severe limiting 
Activities or requiring 
Regular use of pain 
Medications 
 
VARICOSE 
VEINS 
 
None 
 
Few scattered 
 
Multiple; great 
Saphenousveins, confined to 
calf 
And thigh 
 
Extensive; thigh and calf 
or 
Great and small saphenous 
Distribution 
 
VENOUS 
EDEMA 
 
None 
 
Evening ankle 
swelling 
Only 
 
Afternoon 
Swelling, 
Above ankle 
 
Morning swelling above 
Ankle and requiring 
Activity change, elevation 
 
SKIN 
PIGMENTATIO
N 
 
None 
 
Diffuse, but 
limited in 
Area and old 
(brown) 
 
Diffuse over most ofgaiter 
distribution(lowerthird) or 
recent 
Pigmentation (purple) 
 
Wider distribution (above 
Lower third) plus recent 
Pigmentation 
 
INFLAMMATIO
N 
 
None 
 
Mild 
cellulitis, 
limited 
To marginal 
area 
Around ulcer 
 
Moderate cellulitis, 
Involves most of (lower third) 
 
Severe cellulitis (lower 
Third and above) 
Or significant 
 
INDURATION 
 
None 
 
Focal, 
circummalleol
ar 
 
Medial or lateral, lessthan 
lower third of leg 
 
Entire lower third of leg or 
more 
 
NUMBER OF 
ACTIVE 
ULCERS 
 
0 
 
1 
 
2 
 
>2 
 
ACTIVE ULCER 
DURATION 
 
None 
 
<3 months 
 
>3 months, <1year 
 
Not healed>1 year 
 
 
 
ACTIVE ULCER 
DIAMETER 
 
None 
 
<2 
 
2-6 
 
>6 
 
 
 
 
COMPRESSION 
THERAPY 
 
Not used or 
Patient not 
Compliant 
 
Intermittant 
use of 
Stockings 
 
Wears elastic stocking 
Most days 
 
Full compliance, 
Stockings+elevation 
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1
st
 Day 8
th
 Day 15
th
 Day 22
th
 Day 29
th
 Day 36
th
 Day 43
rd
 Day 49
th
 Day 
Vcss 
score 
        
 
Date:          
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                         Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSSPANDITHARHOSPITAL 
CHENNAI – 600 047. 
POST-GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
   
  PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “KUKKIL 
CHOORANAM” (INTERNAL) AND “THUVARA ENNAI” (EXTERNAL) IN THE 
TREATMENT OF   PUN (NAALAVIBATHA VIRANAM-VARICOSE ULCER).  
 
[PRINCIPAL INVESTIGATOR] 
 
       FORM-III – LABORATORY INVESTIGATIONS PROFORMA 
STUDY NO:                       OP / IP NO:                                     AGE/GENDER:    
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TMT  
( DATE) 
AFTER TMT 
(DATE) 
Hb( gm/dl) 
M:12-15 
F:11.5-14 
  
T.WBC (cells/cu.mm) 
4000-
11000 
  
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
T.RBC(million cells/cu.mm) M:4.0-5.5 
  F:3.5-4.5 
  
  ESR(mm/hour) ½ hr. M:1-13 
F:1-20 
  
  1 hr.   
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Blood Investigations Normal Values 
Before TMT 
(DATE) 
After TMT 
(DATE) 
Blood 
glucose 
(mg/dl) 
Fasting    70-110   
PP    80-140   
Random    80-120   
RFT 
(mg/dl) 
Blood urea    16-50   
Serum creatinine    0.6-1.2   
Serum uric acid 
M:3-9  F:2.5-
7.5 
  
LFT 
(mg/dl) 
Total bilirubin    0.2-1.2   
Direct bilirubin    0.1-1.2   
Indirect bilirubin    0.2-0.7   
SGOT  (IU/L)    0-40   
SGPT (IU/L)    0-35   
Alkaline 
phosphatase(IU/L) 
   80-290   
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:           Signature of the HOD 
 
Urine 
investigations 
Before TMT( Date) After TMT ( Date) 
Albumin   
Fasting sugar   
PP sugar   
Deposits   
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FORM V – PATIENT INFORMATION SHEET 
Name of Principal Investigator: Dr.C.Sasikala 
Name of the institute: National Institute of Siddha, 
            Tambaram Sanatorium, Chennai-47. 
I, Dr.C.Sasikala studying M.D(Siddha) at National Institute of  Siddha, 
Tambaram Sanatorium is doing a trial on PUN (Naalavibatha Pun-Varicose 
ulcer).Varicose ulcer is a most common persistent skin disease, occurring throughout 
the world. In this regard, I am in a need to ask you few questions. I will maintain 
confidentiality of your comments and data obtained. There will be no risk of 
disclosing your identity and no physical, psychological or professional risk is 
involved by taking part in this study. Taking part in this study is voluntary. No 
compensation will be paid to you for taking part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal 
medicine KUKKIL CHOORANAM (Internal medicine-1g BD for 48 days) 
andTHUVARA ENNAI(External medicine), if you wish to stay in the In-Patient ward 
Treatment will be provided to you assuring that you will not be definitely hurt in any 
course of treatment. 
 The information I am collecting in this study will remain confidential. I will 
ask you few questions through a questionnaire. It will take approximately 20 min of 
time. Your name won’t be mentioned in the lab investigation form instead a code will 
be used. 
If you wish to find out more about this study before taking part, you can ask 
me all the questions you want or contact Dr.C.Sasikala, PG Scholar cum principal 
investigator of this study, National Institute of Siddha, Chennai-47. You can also 
contact the Member-secretary of Ethics committee, National Institute of Siddha, 
Chennai 600047, and Tel No: 044-22380789 for rights and participation in the study. 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É - ¦ºý¨É 47 
Òñ (¿¡ÇÅ¢À¡¾ Òñ)§¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý (Ìì¸¢ø ÝÃ½õ 
ÁüÚõÐÅÃ ±ñ¦½ö) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É 
¾¸Åø ÀÊÅõ. 
 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷: ÁÕòÐÅ÷ : º¢.ºº¢¸Ä¡ 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷ :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ                            
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý ÁÕòÐÅ÷ 
º¢.ºº¢¸Ä¡ ¿¡ÇÅ¢À¡¾ Òñ ±ýÛõ §¿¡Â¢øÁÕòÐÅ ¬Ã¡öîº¢Â¢ø 
®ÎÀðÎû§Çý.Òñ±ýÛõ §¿¡ö ¯ñ¼¡Å¾ü¸¡É «ÊôÀ¨¼ ¸¡Ã½õ ¸¢ÕÁ¢¸û 
«ýÚ. ¸ðÊ ¯¨¼Å¾É¡Öõ, ¸ÕÅ¢Â¢É¡Öõ, «ÊÀÎÅ¾¡Öõ, ¦¿ÕôÀ¢É¡Öõ, 
À¢È ¯Â¢÷¸Ç¢ý ¸Ê¸Ç¡Öõ ¯ñ¼¡Å¾¡¸ ÜÈôÀÎ¸¢ÈÐ. -Ð ÀÃÅ ÜÊÂ §¿¡ö 
«ýÚ. -ó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç §¸ð¸×õ, §¾¨ÅÂ¡É 
¬öÅ¸ ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý.-Ð ºõÀó¾Á¡É 
¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
-¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ò ¦¾¡¨¸Ôõ ÅÆí¸ôÀ¼ Á¡ð¼¡Ð. -ó¾ 
¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ.-ó¾ ¬Ã¡öîº¢ìÌ ¾í¸û 
Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø ¯ûÁÕó¾¡¸ Ìì¸¢ø ÝÃ½õ, §¾ý (1gm) 
2§Å¨Ç (¸¡¨Ä,Á¡¨Ä) ¯½×ìÌô À¢ý 48 ¿¡ð¸û ¯ð¦¸¡ûÇ §ÅñÎõ. ¦ÅÇ¢ 
ÁÕó¾¡¸ ÐÅÃ ±ñ¦½ö¦ÅÇ¢§Â ¾¼Å §ÅñÎõ. ¦ÅÇ¢ §¿¡Â¡Ç÷¸û 7 
¿¡ð¸ÙìÌ ´ÕÓ¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. ¯û §¿¡Â¡Ç¢Â¡¸ ¾í¸ 
Å¢ÕôÀõ ¦¾Ã¢Å¢ìÌõ Àðºò¾¢ø §¿¡öìÌ ¾Ìó¾  º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. -ó¾ 
¬Ã¡öîº¢Â¢ø §¿¡Â¢ÉÃ¡¸ §º÷ó¾ À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀõ -ø¨Ä¦ÂÉ¢ø 
±ô§À¡Ð §ÅñÎÁ¡É¡Öõ Å¢Ä¸¢ ¦¸¡ûÇÄ¡õ. -ó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ ÁüÈ 
Å¢ÀÃí¸ÙìÌõ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕòÐÅ÷: 
º¢.ºº¢¸Ä¡ (Àð¼ §Áü ÀÊôÀ¡Ç÷ º¢ÈôÒ ÁÕòÐÅ Ð¨È) «Ï¸×õ. ¨¸ô§Àº¢ ±ñ 
9787581114. §ÁÖõ  -ó¾ ¬Ã¡öîº¢ìÌ IEC º¡ýÚ ¦ÀÈôÀðÎûÇÐ. -ó¾ 
ÁÕóÐ º¢ÈôÀ¡¸Òñ §¿¡öì¸¡¸ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø 
ÜÈôÀðÎûÇÐ. ²ü¸É§Å ¯À§Â¡¸ò¾¢ø ¯ûÇ -Ð §À¡ýÈ ÁÕóÐ -ÐÅ¨Ã 
§¿¡Â¡Ç¢¸Ç¢¼õ ±ó¾ Å¢¾Àì¸ Å¢¨Ç×¸¨ÇÔõ ²üÀÎò¾Å¢ø¨Ä. §ÁÖõ ¯½× 
Ó¨ÈÂ¢ø ÁÕòÐÅÃ¡ø ÜÈôÀÎõ Àò¾¢Âõ ¸¡ìÌÁ¡Ú «È¢×Úò¾ôÀÎ¸¢ÈÐ. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
    
   PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “KUKKIL 
CHOORANAM” (INTERNAL) AND “THUVARA ENNAI” (EXTERNAL) IN THE 
TREATMENT OF   PUN (NAALAVIBATHA PUN-VARICOSE ULCER).  
FORM VI: INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have 
had the opportunity to ask questions about it and any questions I have asked have 
been answered to my satisfaction.  
            I consent voluntarily to participate in this study and understand that I have 
the right to withdraw from the study at any time without affecting my further 
medical care”. 
"I have received a copy of the information sheet/consent form". 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                   
 
Date: 
 
Signature of a witness                                                          Left thumb Impression  
                                                                                              Of the Participant     
(Selected by the participant bearing no connection with the survey team)   
 
 
Signature of the Investigator 
 
 Signature of the Lecturer                                                       Signature of the HOD 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É-¦ºý¨É 47 
Òñ (¿¡ÇÅ¢À¡¾ Òñ) §¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý (Ìì¸¢ø ÝÃ½õ 
ÁüÚõÐÅÃ ±ñ¦½ö) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ 
¬öÅ¢ü¸¡É´ôÒ¾ø ÀÊÅõ-¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
¿¡ý -ó¾ ¬ö× ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌ ÒÃ¢Ôõ Å¨¸Â¢ø 
±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 §¾¾¢:                                                     ¨¸¦Â¡ôÀõ: 
-¼õ:                                                      ¦ÀÂ÷     : 
                                       §¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
±ýÉ¢¼õ -ó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ 
ÁÕòÐÅ ÅÆ¢Ó¨È ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø -Âì¸ò¨¾ 
¸ñ¸¡½¢ì¸×õ, «¾¨É À¡Ð¸¡ì¸×õ ÀÂýÀÎõ ÁÕòÐÅ ¬ö×ìÜ¼ 
ÀÃ¢§º¡¾¨É¸û ÀüÈ¢ ¾¢Õô¾¢ «Ç¢ìÌõ Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì 
ÜÈôÀð¼Ð. 
¿¡ý -ó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ±ô¦À¡ØÐ §ÅñÎÁ¡É¡Öõ -ó¾ 
¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â ¦¾Ã¢ó¾¢Õì¸¢ý§Èý. 
¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì ¦¸¡ñÎ Òñ 
(¿¡ÇÅ¢À¡¾ Òñ)§¿¡öì¸¡ÉÌì¸¢ø ÝÃ½õ (¯û ÁÕóÐ)ÁüÚõÐÅÃ ±ñ¦½ö 
(¦ÅÇ¢ ÁÕóÐ) ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢üÌ 
±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø «Ç¢ì¸¢§Èý. 
 
§¾¾¢:                                                     ¨¸¦Â¡ôÀõ: 
-¼õ:       ¦ÀÂ÷ :     
¯È×Ó¨È:                 º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
¦ÀÂ÷:     
Å¢Ã¢×¨ÃÂ¡Ç÷    ¨¸¦Â¡ôÀõ:                            Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSSPANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
     PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “KUKKIL 
CHOORANAM” (INTERNAL) AND “THUVARA ENNAI” (EXTERNAL) IN THE TREATMENT 
OF   PUN (NAALAVIBATHA PUN-VARICOSE ULCER).  
Name of Principal Investigator: Dr.C.SASIKALA   
 
FORM VII -WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE:  
2. OP / IP NO:   
3. NAME:   
4. AGE:  
5. GENDER: 
6. DATE OF TRIAL COMMENCEMENT:  
7. DATE OF WITHDRAWAL FROM TRIAL:  
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
Irregular treatment:                           Yes/ No 
Shift of locality:                                     Yes/No 
Increase in severity of symptoms:     Yes/No 
Development of severe adverse drug reactions:   Yes/No 
Development of adverse event:                                             Yes/No 
 
(If YES, give the details of adverse reaction in Form VII -B – Adverse      
Reaction Form / Pharmaco Vigilance Form) 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                        Signature of the HOD 
 
 
 
 
CASE SHEET PROFORMA 
 
 Page 172 
 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “KUKKIL CHOORANAM” 
(INTERNAL) AND “THUVARA ENNAI” (EXTERNAL) IN THE TREATMENT OF PUN 
(NAALAVIBATHA VIRANAM-VARICOSE ULCER). 
 
Name of Principal Investigator: Dr.C.Sasikala  
 
                                 FORM VIII – DIETARY ADVICE FORM 
 
     §º÷ì¸ ÜÊÂ ¯½×¸û      ¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û 
 
ÓÕí¨¸ôÀ¢ïÍ 
«Å¨ÃôÀ¢ïÍ 
¸¡Ãð 
À£ðåð 
¸Ã¢º¡¨Ä 
¦À¡ýÉ¡í¸ñ½¢ 
Á½ò¾ì¸¡Ç¢              
ÓÕí¨¸ì¸£¨Ã 
Àº¨Äì¸£¨Ã 
º¢Ú¸£¨Ã                 
¸È¢§ÅôÀ¢¨Ä  
¦¸¡ò¾ÁøÄ¢ 
Á¡Ð¨Ç 
¬ôÀ¢û 
§ÀÃ£î¨º 
¾¢Ã¡ð¨º 
¦¸¡öÂ¡                
¿¡Åø 
ºô§À¡ð¼¡ 
¯Ä÷ ¾¢Ã¡ð¨º 
 §Å¸¨Åò¾ ¸¡ö¸È¢¸û 
 
§¸¡Æ¢ì¸È¢ 
Á£ý 
¿ñÎ 
¸ÕÅ¡Î 
 Óð¨¼ 
 À¡ø 
À¡ø ¦À¡Õû¸û 
ÒÇ¢ôÒô ¦À¡Õû¸û 
§Å÷ì¸¼¨Ä 
±ûÙ 
«ýÉ¡º¢ 
¿ø¦Äñ¦½ö  
±ÖÁ¢î¨º 
¾ì¸¡Ç¢ 
ÒÇ¢ôÒ ¾Â¢÷ §Á¡÷ 
°Ú¸¡ö 
¦Àñ§À¡¸õ 
¦ÅüÈ¢¨Ä,À¡ìÌ  
Ò¨¸Â¢¨Ä  
ÁÐ «ÕóÐ¾ø  
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